Measuring And Understanding Health-Related Quality Of Life Among Adult Patients With Hemophilia by Shah, Ruchitbhai Mukesh
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
2016 
Measuring And Understanding Health-Related Quality Of Life 
Among Adult Patients With Hemophilia 
Ruchitbhai Mukesh Shah 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Shah, Ruchitbhai Mukesh, "Measuring And Understanding Health-Related Quality Of Life Among Adult 
Patients With Hemophilia" (2016). Electronic Theses and Dissertations. 743. 
https://egrove.olemiss.edu/etd/743 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
  
 
 
 
 
MEASURING AND UNDERSTANDING HEALTH-RELATED QUALITY OF LIFE AMONG 
ADULT PATIENTS WITH HEMOPHILIA 
 
 
 
 
A Dissertation presented in partial fulfillment of requirements 
for the degree of Doctor of Philosophy 
in the Department of Pharmacy Administration 
The University of Mississippi 
 
 
 
 
by 
RUCHIT SHAH 
August 2016  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2016 by Ruchit Shah 
All rights reserved.
ii 
 
ABSTRACT 
 
Objectives 
The objectives of this study are to: 1) examine the psychometric properties of the Medical 
Outcomes Study Short Form-12 Version 2 (SF-12v2); 2) assess the measurement invariance of 
the SF-12v2 with respect to age, disease severity, and treatment regimen; 3) identify 
psychosocial predictors of health-related quality (HRQOL) among adults with hemophilia in the 
United States. 
Methods  
This cross-sectional study was conducted using both a web-based and paper-based self-
administered survey. Adults with hemophilia were recruited using an online panel, a Facebook 
community of hemophilia patients, and at the University of Mississippi Medical Center 
hemophilia treatment clinic. Psychometric properties of the SF-12v2 were established in terms of 
its construct validity and internal consistency reliability using confirmatory factor analysis 
(CFA). The measurement invariance of the scale was examined using a multi-group CFA based 
approach. Finally, structural equation modeling (SEM) was used to test a theory driven model to 
identify psychosocial predictors of HRQOL in the study sample. 
Results 
A total of 218 adults with hemophilia completed the survey. The SF-12v2 was found to be 
psychometrically valid in the study population. The CFA revealed a two-factor model for the SF-
12v2 instrument similar to what has been previously established in the literature. The instrument 
was found to invariant with respect to age, disease severity, and treatment regimen. Results from 
the SEM analysis suggested that disability, social support, maladaptive coping, and self-efficacy 
were key predictors of HRQOL among adults with hemophilia. 
Conclusions 
The study results indicated that the SF-12v2 is a psychometrically sound instrument to assess 
HRQOL of adults with hemophilia. Considering that the assumption of measurement invariance 
was met, future studies can consider that sub-group comparisons among hemophilia patients in 
terms of HRQOL reflect true differences between groups and are not artifacts of measurement 
bias. Clinicians and caregivers of hemophilia patients should consider factors such as improving 
social support provided, emphasizing on the reduction of maladaptive coping strategies, and 
increasing patient self-efficacy while making key treatment decisions.  
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STUDY OVERVIEW 
 
Hemophilia is a rare X-linked chronic genetic blood coagulation disorder among males that is 
caused by a deficiency of clotting factors VIII or IX.  It impacts about 400,000 people across the 
world and about 20,000 in the United States (US) (Center for Disease Control and Prevention, 
2014; The National Hemophilia Foundation, 2014).  Patients with hemophilia experience 
bleeding into joints and muscles which in severe cases can lead to chronic pain, reduce the range 
of joint motion and eventually progress to chronic arthritis (Dolan et al., 2009).  Also, patients 
with hemophilia often suffer from comorbidities such as infections due to hepatitis C virus 
(HCV), human immunodeficiency virus (HIV), or tolerance to clotting factors in the form of an 
inhibitor (Franchini & Mannucci, 2009).  Thus hemophilia places a significant burden on the 
health-related quality of life (HRQOL) of patients. 
Several studies in the existing literature have assessed the HRQOL of patients with 
hemophilia.  These studies have largely reported that hemophilia impacts the physical HRQOL 
of patients rather than the mental HRQOL, which was found to be comparable to the general 
population (Lindvall, Von Mackensen, & Berntorp, 2012; Miners et al., 1999).  The majority of 
these studies have overlooked the role of psychosocial variables such as social support, coping, 
and self-efficacy and their impact on the HRQOL of hemophilia patients.  Also, none of the 
studies which have evaluated HRQOL among patients with hemophilia have examined the 
psychometric properties of the HRQOL measure used.  An examination of the psychometric 
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properties is essential in order to ensure the appropriateness of the use of an instrument in a 
particular population.  Another key aspect of measuring HRQOL is to make sure that observed 
differences in the HRQOL of the study population are true differences and not measurement 
artifacts.  This can be ensured by assessing the measurement invariance of the HRQOL 
instrument in the study population. 
Therefore the general purpose of this dissertation is to 1) assess the psychometric 
properties of the HRQOL measure used to evaluate the HRQOL of adults with hemophilia; 2) to 
assess measurement invariance of the HRQOL measure used among adults with hemophilia; and 
3) identify psychosocial predictors of HRQOL among adults with hemophilia. 
The remainder of this chapter will provide a brief overview of hemophilia in terms of 
disease etiology, epidemiology, treatments, comorbidities, and impact on patient HRQOL.  
Chapter 1 will also explain the need for and the research significance of this dissertation study.  
Chapter 2 will provide an evaluation of the psychometric properties of an instrument used to 
measure HRQOL (i.e., Short-Form 12 [SF-12v2] in case of this study) among adults with 
hemophilia.  Chapter 3 will assess the measurement invariance of the SF-12v2 among adults 
with hemophilia.  Finally, chapter 4 will assess psychosocial determinants of HRQOL among 
adults with hemophilia by employing a theoretical framework. 
Hemophilia 
Overview of the disease 
 Hemophilia is a rare X-chromosome linked, recessively inherited disorder characterized 
by excessive bleeding and impaired coagulation (Gater, Thomson, & Strandberg-Larsen, 2011).  
Genetically, hemophilia is caused by the transmission of a recessive gene for blood clotting 
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factor/s on the X-chromosome.  Therefore hemophilia occurs mostly in males although females 
can be affected in rare instances.  The two most common forms of hemophilia are hemophilia A 
(Factor VIII deficiency or classic hemophilia) and hemophilia B (Factor IX deficiency or 
Christmas disease).  Hemophilia A and B are considered to be comparable in terms of genetic 
inheritance and clinical manifestation, although recent studies have indicated hemophilia B to be 
less severe (Mannucci & Franchini, 2013) in terms of bleeding frequency and long-term 
outcomes such as joint arthroplasty (Tagariello et al., 2006).  Depending upon the level of 
residual plasma coagulation factor (i.e.,Factor VIII or IX), three levels of disease severity can be 
distinguished among patients with hemophilia. Individuals are defined as being ‘severe’ with the 
representative clotting factor activity level below 1%, ‘moderate’ with factor activity level 
between 1% and 5%, and ‘mild’ with factor activity level between 5% and 40% (White et al., 
2001) of normal.  About 50% - 70% of patients with hemophilia have severe hemophilia 
(National Hemophilia Foundation, 2012). 
Epidemiology 
Hemophilia is the most common bleeding disorder and its current worldwide prevalence 
is about 400,000 individuals.  Hemophilia A affects about 80-85% of the hemophilic population 
and occurs in about 1 in every 5000 male births (National Hemophilia Foundation, 2014).  The 
incidence of hemophilia B is approximately 1 in 30,000 male births (Bolton-Maggs & Pasi, 
2003).  The exact prevalence of the disease in the US is not known.  A 1994 study by Soucie and 
colleagues estimated about 17,000 prevalent cases of hemophilia in the US (Soucie, Evatt, & 
Jackson, 1998). Based on the expected births and deaths since 1994, the CDC estimates the 
current US prevalence of the disease to be at about 20,000 (Centers for Disease Control and 
Prevention, 2014).    
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Disease etiology  
 Patients with hemophilia suffer from frequent bleeding into joints and muscles especially 
into the knees, ankles and elbows and to a lesser extent into hips, shoulders and larger muscle 
groups. Repeated and prolonged bleeding episodes progressively damage the joints and result in 
irreversible hemophilic arthropathy, chronic pain and reduction in the joint range of motion 
(Choinière & Melzack, 1987; Dolan et al., 2009).  Arthropathy is especially common among 
adults who did not have any access to factor replacement home therapy when they were younger 
(Franchini & Mannucci, 2009).  In mild hemophilia, bleeding usually ensues after sustaining an 
injury or after dental or surgical procedures.  However, in more severe cases, patients may 
experience spontaneous bleeds which can affect daily functioning and contribute to disability 
(Poon, Pope, & Tarlov, 2013).     
Treatment of hemophilia 
 Replacement of the deficient coagulation factor by intravenous infusion, in order to stop 
bleeding when it occurs or to prevent it altogether, is the basis of hemophilia treatment 
irrespective of the disease type and/or the severity level (Lindvall, Colstrup, Loogna, Wollter, & 
Grönhaug, 2010).  Providing treatment when bleeding occurs is called ‘on-demand’ treatment.  
During on-demand therapy, intravenous infusions are administered once or twice a day until 
complete healing occurs.  The length of treatment could range from a day in case of minor bleeds 
to a month for more severe episodes.  During preventive therapy or ‘prophylaxis’ patients are 
infused with the missing clotting factor regularly (2-4 times a week) for long periods of times 
(from a few months to years) in order to decrease the frequency or completely stop the 
occurrence of bleeding episodes.  Prophylaxis is considered to be the treatment of choice for 
children and for patients suffering from severe hemophilia.  Prophylaxis started within the first 
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three years of life before repeated joint bleeds is known as ‘primary prophylaxis’ while that 
which is started after the first few bleeds to prevent joint damage is known as ‘secondary 
prophylaxis’ (Berntorp et al., 1995).  Prophylaxis has been linked to fewer bleeding episodes and 
reduced rate of joint deterioration as compared to on-demand therapy (Nilsson, Berntorp, 
Löfqvist, & Pettersson, 1992).      
Comorbidities in patients with hemophilia 
   Before the introduction of efficacious viral inactivation methods in 1985-1987, more 
than 90% of patients with hemophilia who were treated with plasma derived factor concentrates 
became infected with HCV.  Almost 20-30% of these individuals developed a chronic infection 
which progressed to liver cirrhosis (Franchini & Mannucci, 2009).  About half of the HCV-
infected patients with hemophilia also suffer from concomitant HIV infection.  Concomitant HIV 
infection promotes HCV replication which leads to greater liver inflammation and can ultimately 
progress to liver failure (Franchini, 2004).  Angelotta et al. (2007) estimated that about 30% and 
11% of patients with hemophilia in the US were infected with hepatitis C virus (HCV) and 
human immune-deficiency virus (HIV) respectively (Angelotta et al., 2007).     
 Also, the development of inhibitor antibodies to clotting factor concentrates can interfere 
with effective replacement therapy and cause bleeds that are difficult to treat.  As many as 20% 
to 33% of patients with moderately severe and severe forms of hemophilia develop inhibitors 
(DiMichele, 2000).  These patients are at a high risk of suffering from debilitating physical 
limitations and progressive joint bleeds (Leissinger, Cooper, & Solem, 2011).     
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Economic burden of hemophilia 
 Management of hemophilia is associated with high costs for patients, payers and for the 
overall healthcare system.  The primary driver of cost for managing hemophilia, irrespective of 
the treatment regimen, is the cost incurred for the clotting factor concentrates.  Other direct costs 
such as those associated with treatment visits, hospitalizations, emergency room visits, and 
laboratory tests form only a fraction of the total expense (Globe, Curtis, Koerper, & HUGS 
Steering Committee, 2004).  As a part of the Hemophilia Utilization Group Study (HUGS), 
Globe et al. (2004) estimated the annual direct cost of hemophilia A care to be $139,102 per 
person.  Clotting factor consumption alone accounted for between 45% (for mild hemophilia) to 
83% (for severe hemophilia) of the total direct cost of care (Globe et al., 2004).  Other studies 
have reported similar findings among Medicaid as well as commercially insured patients with 
hemophilia (Guh, Grosse, McAlister, Kessler, & Soucie, 2012a, 2012b; Tencer, Friedman, Li-
McLeod, & Johnson, 2007; Zhou et al., 2015).       
 Johnson et al. estimated the indirect cost of care among adults with hemophilia to be 
$12,721 per person annually (Johnson et al., 2012).  Indirect costs were calculated in terms of 
productivity loses due to absenteeism from work, time spent in arranging hemophilia care and 
unpaid caregiver support.  These costs form a small, albeit an important, portion of the total 
burden of the disease and could have a significant impact on patients and their families. 
Health-related quality of life (HRQOL) 
The World Health Organization (WHO) defines health as “not merely the absence of 
disease or infirmity, but as a state of complete physical, mental and social well-being” (Bullinger 
& von Mackensen, 2004).  HRQOL refers to “patients’ appraisal of their current level of 
8 
 
functioning and their satisfaction with it compared with what they perceive to be ideal health” 
(Fischer, van der Bom, & van den Berg, 2003).  HRQOL is thus a subjective representation of 
the patient’s health.  It incorporates those physical, mental, social, and emotional aspects of well-
being and functioning which matter to patients because patients may not be sensitive to changes 
in clinical or physiologic disease measures (Bullinger & von Mackensen, 2004).  In fact people 
with similar disease severities could have different evaluations of their HRQOL (Guyatt, Feeny, 
& Patrick, 1993).  Thus HRQOL has become an important outcome which must be assessed in 
order to ensure optimum treatment and resource allocation decisions (Fischer et al., 2003). 
 For a patient living with hemophilia, merely treating and preventing bleeding episodes 
and other physical symptoms using clotting factor concentrates is not enough.  Patients with 
hemophilia must be careful about participating in activities such as contact sports because 
immediate bleeding may ensue.  Long-term impairments in mobility and impact on functional 
status due to reduced range of joint motion may also limit the activities in which patients can 
participate.  This can affect social participation and peer integration (Aznar, Magallón, Querol, 
Gorina, & Tusell, 2009; Mackensen, 2007).  Employment and occupational disabilities can occur 
as well.  Also, the disease can influence the mental well-being of patients within whom signs of 
depression, anxiety and psychological distress are common (Ghanizadeh & Baligh-Jahromi, 
2009).  Thus the physical, mental and social consequences of the disease serve to reduce the 
HRQOL of patients.  Therefore HRQOL assessment is now recognized as an important health 
outcomes endpoint which can help decide and optimize treatment options among patients with 
hemophilia (Fischer et al., 2003). 
Several studies have assessed the HRQOL of patients with hemophilia.  The majority of 
these studies have reported that patients with hemophilia suffer from worse physical HRQOL as 
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compared to the healthy population.  The mental HRQOL of patients with hemophilia was found 
to be similar to the general population (Aznar et al., 2009; Lindvall et al., 2012; Molho et al., 
2000; Poon, Doctor, & Nichol, 2014).  Studies have also reported the beneficial impact of 
prophylaxis as compared to on-demand treatment on the physical HRQOL of patients with 
hemophilia (Royal et al., 2002; Szucs, Öffner, and Schramm, 1996).  Higher disease severity, 
greater age and the presence of comorbidities such as HCV, HIV or inhibitors have also been 
associated with significant impairments in HRQOL among hemophilia patients (Brown, Lee, 
Joshi, & Pashos, 2009; Djulbegovic et al., 1996; Posthouwer et al., 2005). 
Types of HRQOL measures 
A key consideration in HRQOL assessment is the use of an appropriate instrument.  A 
good HRQOL tool should have the ability to discriminate between individuals based on their 
health status (Guyatt et al., 1993).  Therefore it is recommended that the psychometric properties 
of a HRQOL measure be established in terms of its validity, reliability, and responsiveness 
before its use in a particular population (Patrick & Deyo, 1989).  Studies in the literature have 
used three types of measures to assess HRQOL among patients with hemophilia: generic 
measures, disease-specific instruments, and utility-based measures.  Generic instruments allow 
for comparison of patients’ health status across disease states and conditions (Coons, Rao, 
Keininger, & Hays, 2000).  However, they are often criticized as being less sensitive to certain 
key aspects or symptoms of a particular disease state and as a result may not be able to capture 
small but important changes in the HRQOL of patients (Guyatt et al., 1993).     
Disease-specific measures of HRQOL on the other hand concentrate on problems that are 
relevant to the patients of a particular disease and its treatment consequences (Bullinger, Globe, 
Wasserman, Young, & Von MacKensen, 2009).  However, they cannot be used to compare 
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HRQOL across different disease states.  Such information may be important to clinicians and 
policy makers in making key treatment and resource allocation decisions.  Utility-based 
measures summarize the positive and negative aspects of HRQOL into a single health-state 
preference (Bennett, Torrance, & In, 1996).  Health utilities are an important component of cost-
utility analyses because they are used as weights for the calculation of quality-adjusted life-years 
(QALYs).  Availability of newer and more expensive hemophilia treatment options, the scarcity 
of resources available at the disposal of payers, and the rarity of this disease make health utilities 
essential to justify resources allocated to a particular treatment option (Guyatt et al., 1993; 
Torrance, 1976). 
It is very important to assess the psychometric properties of measures of HRQOL before 
they can be employed across different patient populations.  Psychometric assessments provide 
evidence about the appropriateness of use of measures of HRQOL in a particular group of 
patients.  When testing HRQOL differences between groups of patients using a well-established 
measure of HRQOL, it is also fundamental that members of different groups assign the same 
meaning to questionnaire items.  If it can be shown that patient characteristics (such as age, 
gender, type of disease, disease severity) do not affect the psychometric properties of the 
observed indicators (i.e., questionnaire items), then the assumption of measurement invariance is 
not violated.  If the assumption of measurement invariance holds, then the observed differences 
in HRQOL among groups defining the study populations are true differences in HRQOL and not 
measurement artifacts. 
Generic measures of HRQOL 
The most commonly used generic HRQOL instrument among patients with hemophilia 
was the Medical Outcomes Study (MOS) Short-Form 36 (SF-36) (Ware & Sherbourne, 1992).  A 
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handful of studies have used the Short Form-12 health survey (SF-12) (Brown et al., 2009; Poon 
et al., 2013) which is a shorter version of the SF-36 (Ware, Kosinski, & Lincoln, 2001).  These 
instruments capture information regarding eight dimensions of patient health (i.e., physical 
functioning, role-physical, bodily pain, general health, vitality social-functioning, role-emotional, 
and mental health).  These eight dimensions can be further aggregated into two summary scores: 
the physical component summary (PCS) and the mental component summary (MCS) score. 
A German study found that patients on prophylaxis had better HRQOL as compared to 
those on on-demand treatment specifically in terms of three dimensions: general health, role-
physical and role-emotional (Szucs, Öffner, and Schramm, 1996).  Szucs et al. also found that 
patients with hemophilia had significantly greater limitations in terms of physical activity, pain 
and general health as compared to healthy men.  Royal et al. (2002) reported similar findings in a 
study comparing the HRQOL of prophylaxis and on-demand therapy patients across 16 
European hemophilia clinics.  In a United Kingdom (UK) study, Miners et al. (1999) showed that 
irrespective of age, patients with severe hemophilia recorded a lower HRQOL as compared to 
both the general population as well as moderate/mild hemophiliacs (Miners et al., 1999).  Poon 
and colleagues conducted a retrospective analysis of HRQOL data which were collected using 
the SF-12v1 as a part of the HUGS.  This is a multicenter cohort study of patients from six 
hemophilia treatment centers (HTCs) across the US.  The analyses revealed that adults with 
severe hemophilia A had a lower physical HRQOL as compared to the US norm population but a 
comparable mental HRQOL.  Physical HRQOL was poorer for patients with severe form of the 
disease (i.e., those who reported greater joint pain and reduced range of motion) as compared to 
patients suffering from mild/moderate forms of the disease (Poon et al., 2013).  Duncan et al. 
(2012) showed that adults with hemophilia in the US who had always been on prophylaxis 
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therapy reported better physical functioning and physical HRQOL, assessed using the SF-12v2, 
than those who had not been on prophylaxis throughout their life (Duncan, Kronenberger, 
Roberson, & Shapiro, 2012).  Impairments in the physical HRQOL of patients with hemophilia 
as compared to the healthy population were found in studies conducted in Spain, Sweden, 
France, and the US (Aznar et al., 2009; Klamroth et al., 2011; Lindvall et al., 2012; Molho et al., 
2000). 
Disease-specific measures of HRQOL 
Four disease-specific measures of HRQOL have been developed and tested among adults 
with hemophilia.  These are the Hem-A-QOL, HAEMO-QOL-A, Hemofilia-QOL, and the 
Hemolatin-QOL (Arranz et al., 2004; Remor et al., 2005; Rentz et al., 2008; von Mackensen & 
Bullinger, 2004).  However, the HAEMO-QOL-A is the only measure which has been validated 
in a sample of patients with hemophilia in the US (Rentz et al., 2008).  In addition to capturing 
information about the impact of hemophilia on the physical and mental health of patients, these 
instruments also assess the detrimental impact of the disease in terms of consequences of 
bleeding, joint damage, treatment satisfaction, treatment concerns, treatment difficulties, and 
impact on relationships and social activity.   
Studies which have employed disease-specific HRQOL instruments among patients with 
hemophilia have reported a similar pattern of findings as compared to those which utilized 
generic HRQOL measures (Arranz et al., 2004; Rentz et al., 2008).  Disease severity and type of 
treatment were found to be significantly associated with physical HRQOL.  Overall, the disease 
was found to have a considerable negative impact on the physical functioning of patients.   
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Theoretical framework for understanding HRQOL in hemophilia 
There is a lack of clarity on what dimensions of a patient’s life (i.e., physical, 
psychological, emotional, and social) contribute to their HRQOL in case of rare genetic blood 
coagulation disorders.  Most of the studies which have assessed predictors of HRQOL among 
patients with rare diseases have been limited in their use of a conceptual framework.  Using a 
theoretical framework can help researchers better understand HRQOL and its underlying 
determinants.  Wilson and Cleary’s (1995) conceptual model of patient outcomes is the most 
commonly used conceptual model for understanding and identifying predictors of HRQOL 
(Wilson & Cleary, 1995).  Wilson and Cleary’s model causally links five key dimensions of 
patient outcomes: (1) biological and physiological factors; (2) symptom status; (3) functional 
status; (4) general health perception; and (5) overall quality of life.     
The use of theories of adaptation have been recommended in order to frame a holistic 
understanding of quality of life (QOL) among patients with rare genetic disorders (Cohen, 
Biesecker, & Part, 2010).  QOL is a broad construct which includes an individual’s physical, 
psychological, and social health, and its relationship with the environment.  It includes both 
health and non-health related factors such as financial status, housing and living conditions, and 
environment.  Adaptation, in the context of a chronic disease, can be defined as “the process of 
coming to terms with the implications of a health threat and the observable outcomes of that 
process” (Biesecker & Erby, 2008).  QOL has been previously treated as an adaptation outcome 
(Stanton, Collins, & Sworowski, 2001).  HRQOL refers to the impact of an individual’s health 
and illness on their QOL (Bennett et al., 1996).  Therefore HRQOL can be conceptualized as an 
outcome of the adaptation process as well.   
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Biesecker and Erby (2008) have suggested that stress and coping are concepts which can 
be influenced by clinicians and therefore theoretical models based on stress and coping theories 
are particularly well suited for HRQOL research in rare genetic disorders.  The Lazarus and 
Folkman’s (1984) cognitive-behavioral model is based on a theory of stress, appraisal, coping, 
and adaptation.  According to this theory, individuals respond to stressors, such as living with 
hemophilia, by making cognitive and emotional appraisals of the stressor.  An individual’s 
appraisal of these stressors depends upon the personal significance of the stressor, its cause, 
severity, one’s susceptibility to the stressor as well as the ability to cope with the problems and 
the emotions associated with the stressor (Lazarus & Folkman, 1984).  These appraisals govern 
coping behaviors because the likelihood that one can change or adapt to a stressor will direct 
one’s ability to cope with it and also determine the coping mechanism which will be adopted 
(Bombardier, D’Amico, & Jordan, 1990).  These coping strategies in turn gradually help attain or 
restore optimal HRQOL.  Therefore an individual’s ability to adapt to a stressor is mediated by 
cognitive appraisal of the stressful event and the associated coping response.  This model can 
therefore be adapted to identify psychosocial predictors of HRQOL among patients with rare 
diseases such as hemophilia. 
A Dutch study has previously adapted Lazarus and Folkman’s theory of stress and 
appraisal to examine the influence of appraisal, health beliefs, psychological characteristics and 
social support on well-being among hemophilia patients (Triemstra et al., 1998).  Psychological 
characteristics were found to be the strongest determinants of patient well-being and partially 
mediated the negative impact of disability on well-being.  The mediating role of cognitive 
appraisal and social support in the relationship between disability and well-being remained 
unclear.  The study by Triemstra et al. (1998) was by far the most comprehensive study which 
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outlined the development and evaluation of a structural equation model in establishing the 
consequences of hemophilia.  However, this study was carried out in a non-US setting and did 
not measure HRQOL as the adaptation outcome of interest among patients with hemophilia.  
Also the impact of key variables, such as self-efficacy and coping, which have been shown to 
significantly impact HRQOL among patients with hemophilia (Binnema, Schrijvers, Bos, 
Schuurmans, & Fischer, 2014; Catalan et al., 1992; Lock et al., 2014) was not assessed.
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NEED FOR THE STUDY 
1. Need to test the psychometric properties of the health status measure among adult 
patients with hemophilia. 
 
The SF-12 has been previously used to assess HRQOL among patients with hemophilia 
(Poon, 2013; Duncan et al., 2012).  However, its psychometric properties in this 
population have not been assessed.  In order to obtain evidence about the appropriateness 
of use of the SF-12v2 among hemophilia patients, it is imperative to test its psychometric 
properties.  Psychometric assessments are necessary to ensure the broad application of 
such generic HRQOL instruments across different populations.  Therefore this study 
determined the psychometric properties of the SF-12v2 among adult patients with 
hemophilia in the US.  The psychometric properties of the SF-12v2 were determined in 
terms of its convergent validity, discriminant validity, known-groups validity, factorial 
validity, and internal consistency reliability.  Floor and ceiling effects were also 
examined on a per item basis for the HRQOL instrument under consideration. 
 
2. Need to assess measurement invariance of the health status measure among adult patients 
with hemophilia
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The assumption of measurement invariance must be tested in order to ensure that the 
differences observed in the HRQOL of the study populations are true differences and not 
measurement artifacts.  An important question to keep in mind when using a HRQOL 
measure to assess the health status of patients with a given disease state is whether 
different members of the study population assign the same meaning to questionnaire 
items.  In the context of the current study, the assumption of measurement invariance was 
said to be met if specific characteristics such as age, disease severity, and treatment 
regime did not influence observed responses to the items on the SF-12v2.  If this 
assumption is violated then differences in HRQOL between hemophilia patients may not 
be true differences.  In fact inherent differences in terms of factors such as age, disease 
severity, and treatment regimen may be manifested as differences in HRQOL among 
patients with hemophilia. 
 
3. Need to assess psychosocial predictors of HRQOL among adult patients with hemophilia. 
 
While previous studies have emphasized on clinical and socio-demographic determinants, 
this was the first US-based study which critically shifts focus to an assessment of 
psychosocial predictors of HRQOL among patients with hemophilia.  An adapted version 
of the Lazarus and Folkman’s cognitive-behavioral model of stress, appraisal, and coping 
was employed in order to help us examine the interplay between the patient’s use of 
resources (i.e., social support, coping strategies, and self-efficacy) and adaptational health 
outcomes such as HRQOL.  Employing a theory-based approach is essential to truly 
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understand the impact of hemophilia on patient well-being.  Knowledge about these 
psychosocial factors will not only assist healthcare providers and caregivers in improving 
care provided to individuals with hemophilia, but will also enable patients to better 
understand and self-manage their disease condition.  Such assessments can assist both 
clinicians and healthcare policymakers in designing programs aimed at increasing the 
level of social support provided, fostering the use of adaptive coping strategies, and 
overall ensuring better health among these patients. 
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SPECIFIC AIMS AND OBJECTIVES 
1. To examine the psychometric properties of the SF-12v2 among adult hemophilia patients 
in the United States 
a. Assess the construct validity (convergent validity, discriminant validity, known-
groups validity, factorial validity) of the SF-12v2 instrument. 
b. Assess the reliability and floor and ceiling effects of the SF-12v2 instrument. 
2. To assess the measurement invariance of the SF-12v2 among adult hemophilia patients in 
the United States 
a. Assess the presence of measurement invariance bias in a sample of US adults with 
hemophilia, specifically focusing on whether age, disease severity, and treatment 
regimen result in biased HRQOL scores measured using the SF-12v2. 
3. To evaluate psychosocial predictors of HRQOL among adult hemophilia patients in the 
United States 
a. Identify psychosocial determinants of HRQOL in a sample of US adults with 
hemophilia by employing an adapted version of the Lazarus and Folkman’s 
cognitive-behavioral model of stress, appraisal, and coping.  This study will 
specifically assess the relationship between disability, social support, coping, self-
efficacy, and HRQOL among adult hemophilia patients using a structural 
equation model. 
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CHAPTER II: AN EVALUATION OF THE PSYCHOMETRIC PROPERTIES OF 
THE SHORT FORM-12 (SF-12) AMONG ADULTS WITH HEMOPHILIA IN 
THE UNITED STATES 
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INTRODUCTION 
Hemophilia is a rare X-linked chronic genetic blood coagulation disorder predominantly among 
males that is caused by a deficiency of clotting factors VIII or IX in blood plasma.  It affects 
about 400,000 people across the world and about 20,000 in the United States (US) (Center for 
Disease Control and Prevention, 2014; National Hemophilia Foundation, 2014).  Patients with 
hemophilia experience bleeding into joints and muscles which in severe cases can lead to chronic 
pain, reduce the range of joint motion and eventually progress to chronic arthritis (Dolan et al., 
2009).  Also, hemophilia patients often suffer from comorbidities such as infections due to 
hepatitis C virus (HCV), human immunodeficiency virus (HIV), or tolerance to clotting factors 
in the form of an inhibitor (Franchini & Mannucci, 2009).   
 According to the International Society for Quality of Life Research (ISOQOL), health-
related quality of life (HRQOL) is “the functional effect of a medical condition and/or its 
consequent therapy upon a patient.” (International Society for Quality of Life Research, 2015).  
Thus HRQOL is a multidimensional, subjective concept which incorporates physical 
functioning, psychological functioning, social interaction, and somatic sensation. Hemophilia 
places a significant burden on the HRQOL of patients.  Therefore, HRQOL has evolved as an 
important outcome which must be assessed among patients with hemophilia in order to truly 
quantify the burden of this disease. 
 The SF-12 Health Survey version 2 (SF-12v2) is a commonly used generic health status 
measure (Ware, Kosinski, & Keller, 1996).  The SF-12 is an abbreviated version of the SF-36, a 
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widely used generic self-report measure of HRQOL.  Like the SF-36, the SF-12 captures 
information regarding eight dimensions of patient health (i.e., physical functioning, role-
physical, bodily pain, general health, vitality social-functioning, role-emotional, and mental 
health).  It also provides two summary measures: the physical component summary score (PCS) 
and mental component summary score (MCS), which aggregate the eight domains. 
 The SF-12 was first psychometrically validated in the general US population by Ware 
and colleagues in 1996 using data from the National Survey of Functional Health Status 
(NSFHS) and the Medical Outcomes Study (MOS).  The instrument has since been validated 
among general populations in several different countries such as Denmark, Germany, United 
Kingdom, Netherlands, and others (Gandek et al., 1998; Hanmer, Lawrence, Anderson, Kaplan, 
& Fryback, 2006; Kontodimopoulos, Pappa, Niakas, & Tountas, 2007; Montazeri, Vahdaninia, 
Mousavi, & Omidvari, 2009) as well as among patients with several diseases such as Parkinson’s 
disease, stroke, diabetes mellitus, inflammatory rheumatic disease, hemodialysis and others 
(Jakobsson, Westergren, Lindskov, & Hagell, 2012; Maurischat, Ehlebracht-König, Kühn, & 
Bullinger, 2006; Maurischat, Herschbach, Peters, & Bullinger, 2008; Okonkwo, Roth, Pulley, & 
Howard, 2010; Pakpour et al., 2011).  The results of these past studies suggest that the SF-12 has 
good psychometric properties.   
Although the SF-12 has been used to assess the HRQOL of hemophilia patients (Duncan, 
Shapiro, Ye, Epstein, & Luo, 2012; Poon, Doctor, & Nichol, 2014), the psychometric properties 
of the SF-12v2 have never been established among patients with hemophilia.  In order to obtain 
evidence about the appropriateness of use of the SF-12v2 among hemophilia patients, it is 
imperative to test its psychometric properties.  Psychometric assessments are necessary to ensure 
the broad application of such generic HRQOL instruments across different populations (Patrick 
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& Deyo, 1989).  Therefore this study determined the psychometric properties of the SF-12v2 
among adult patients with hemophilia in the US.  The psychometric properties of the SF-12v2 
were determined in terms of its convergent validity, discriminant validity, known-groups 
validity, factorial validity, and internal consistency reliability.  Floor and ceiling effects were 
also examined for the HRQOL instrument under consideration. 
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METHODS 
Study Design  
The current study employed a prospective, cross-sectional, descriptive design by means 
of a web-based self-administered survey which was distributed to a national convenience sample 
of adults with hemophilia in the United States.  Study approval was obtained from the University 
of Mississippi Institutional Review Board under the exempt status. 
Study Sample 
 For the purposes of the current study, the study sample included adults (≥ 18 years of 
age) with hemophilia A or B.  Patients with other blood coagulation disorders such as Von 
Willebrand’s disease were excluded from the study sample.  The sample was recruited with the 
help of a market research vendor company called Rare Patient Voice which maintains a panel of 
hemophilia patients.  The majority of these patients were recruited at hemophilia-related 
conferences and patient advocacy group meetings across the US.  Considering hemophilia is a 
rare disease, patients were also recruited using a Facebook community of hemophilia patients 
called Hemo Friends and at the University of Mississippi (UMMC) hemophilia treatment center 
(HTC) in order to maximize the analyzable sample size for the current study.  Given the nature 
of the statistical analysis plan for this study (i.e., structural equation modeling), an a priori 
sample size of 200 patients with hemophilia was considered to be adequate (Kline, 2005). 
Study methodology 
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This study was a part of a bigger study assessing psychosocial predictors of HRQOL among 
patients with hemophilia. However, only information pertinent to the current study has been 
reported here.  The survey instrument for the current study included the following measures: SF-
12v2, and the demographic and health information form.  Study participants were initially sent 
an email explaining the objective and scope of the study.  This email assured the respondents that 
their information would be kept confidential.  The email also contained a URL link to the survey 
which was programmed in Qualtrics (Qualtrics Inc, Provo, UT).  The survey was open for a 
period of 3 months from October 31, 2015 to January 31, 2016.  All respondents were provided 
$10 Amazon gift cards for participation in the study.   
Study Measures 
SF-12 Health Survey Version 2 (SF-12v2).  The SF-12 is the shorter version of the SF-36 which 
was also developed as a part of the Medical Outcomes Study.  The SF-12v2 is a generic health 
profile instrument with 12-items which compose 8 health concepts forming a health profile 
(Ware et al., 1996).  These eight sub-domains are: physical functioning (PF), role physical (RP), 
bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional 
(RE), and mental health (MH).  These eight sub-domain scores can be weighted and summarized 
into two component scores – the physical component summary (PCS) score and the mental 
component summary (MCS) score.  According to the theoretical test model, the items from the 
physical functioning, role-physical, bodily pain, and general health domain are indicators of PCS 
while vitality, social functioning, role-emotional, and mental health items are indicators for the 
MCS.  The items have different levels of response categories (two, three, five or six).  Using 
item-specific indicator weights, the PCS and MCS scores are calculated using the QualityMetric 
SF Health OutcomesTM Scoring Software.  The SF-12 scores obtained using the scoring software 
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can be transformed onto a 0 to 100 scale with higher scores indicating better HRQOL.  For the 
SF-12v2, the norm-based scores for the general US population have a mean of 50 and a standard 
deviation of 10 with higher scores indicating a better health status (Ware & Kosinski, 2001).  
The SF-12v2 takes about two minutes to complete. 
Patient Global Impression of Severity (PGI-S). The PGI-S is a single self-reported measure that 
asks respondents to rate the severity of their disease condition. In this study, the PGI-S was 
specifically worded as “When thinking about all of the hemophilia-related symptoms that you 
may have experienced during the past 7 days, please circle the one number that best describes 
how your symptoms overall have been; on a 4-point scale scored as: (1) “no symptoms”, (2) 
“mild symptoms”, (3) “moderate symptoms”, or (4) “severe symptoms”. A similar self-report 
symptom severity measure has been previously used among male subjects with lower urinary 
tract symptoms secondary to benign prostatic hyperplasia and women with stress urinary 
incontinence (Viktrup, Hayes, Wang, & Shen, 2012; Yalcin & Bump, 2003). 
Demographic and health information form.  Information was collected for the following socio-
demographic and clinical characteristics: (1) age, (2) race/ethnicity, (3) education status, (4) 
marital status, (5) occupation status, (6) disease severity, (7) monthly bleeding frequency, (8) 
type of treatment, (9) hemophilia-related comorbidities. 
 
Statistical Analysis    
Sample description 
Descriptive statistics were calculated in the form of frequencies and percentages for categorical 
variables, and means and standard deviations for the continuous variables.     
Item-level analysis and floor and ceiling effects 
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Item-level descriptives were calculated in terms of means, and standard deviations (SD).  The 
item-response patterns were presented as the frequency and percentage of each response (missing 
data, if any, was treated as a category with the number of subjects with missing responses 
included in the calculation of the percentages).  Kurtosis and skewness coefficients were 
calculated in order to check for multivariate normality.  Variables with absolute value of the 
skew index > 3.0 and kurtosis index > 10.0 were considered to be non-normal and warranted 
further examination (Kline, 2005).   
Missing data analysis 
The missing score handling technique (Missing Score Estimation) developed by QualityMetricTM 
was used for handling missing responses on the SF-12v2.  For confirmatory factor analysis 
which was used for establishing the factorial validity of the SF-12v2, the total available sample 
was used for the analysis rather than the listwise deletion approach (Asparouhov & Muthén, 
2010). 
Factorial validity.  Confirmatory factor analysis (CFA) was applied to the raw data in order to 
evaluate the factor structure of the SF-12v2 among patients with hemophilia.  CFA is a structural 
equation modeling technique which is used to evaluate the fit of a theoretically-based 
measurement model (Hair, Black, Babin, Anderson, & Tatham, 2009).  Three measurement 
models for the SF-12v2 were tested.  The first was a 1-factor model which forced all the items on 
the SF-12 to load onto a single latent factor.  The second was a 2-factor model based on the 
approach adopted by Okonkwo and colleagues (2010) where the PF, RP, and BP sub-domain 
items were allowed to load onto a latent physical health factor (LPF) while the RE and MH items 
were allowed to load onto a latent mental health factor (LMF).  The three items from the GH, 
VT, and SF domain were allowed to cross load onto both latent factors.  The residuals for the 
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two PF items were allowed to be correlated in both the 1-factor and 2-factor models.  Model 3 
was based on the 2-factor model employed by Maurischat and colleagues (2008) where the GH, 
PF, RP, and BP sub-domain items were allowed to load onto a LPF.  The RE, MH, VT, and SF 
sub-domain items were allowed to load onto a LMF.  The residuals for each of the two PF, RP, 
RE, and MH items were allowed to be correlated.  The LPF and LMF were also correlated in 
models 2 and 3.   
Considering that the items on the SF-12 are measured on an ordinal scale with a limited 
number of response options, weighted least squares estimation (WLSMV) for categorical 
indicators was used to quantify the hypothesized relationships (Muthén, 1984).  All CFA models 
were estimated using Mplus version 7.31 (Muthen & Muthen, Los Angeles, CA).     
 Model fit for each model was assessed using the following five fit statistics:  χ2 statistic, 
the root mean square error of approximation (RMSEA), the Tucker Lewis Index (TLI), the 
comparative fit index (CFI), and the weighted root mean square residual (WRMR).  Bagozzi and 
Yi (2012) suggest that for a well-fitting model, the RMSEA, TLI, CFI must be ≤ 0.08, ≥0.92, and 
≥0.93 respectively (Bagozzi & Yi, 2012).  For a good fitting model, WRMR must be less than or 
equal to 1 (Yu, 2002). 
Convergent validity.  Items which are indicators of a particular latent construct must share a high 
proportion of variance in common.  This is known as convergent validity.  Factor loadings and 
average variance extracted (AVE) from the CFA models and item-scale correlations were used to 
estimate the relative amount of convergent validity among item measures.   
 The size of the factor loading is an indication of the amount of variance in a particular 
item that is explained by the latent construct.  For the current study, standardized factor loadings 
of 0.5 or higher were considered to be indicative of good construct validity (Hair, Anderson, 
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Tatham, Black, & River, 2010).  Statistical significance of the factor loadings was the minimum 
requirement because a significant loading could be weak or moderate in strength. 
 AVE for each latent construct was computed as the total of all squared standardized 
factor loadings divided by the number of items loading onto that factor.  An AVE of 0.5 or 
higher was considered to be suggestive of good convergent validity because an AVE below 0.5 
indicates that the error variance remaining in the indicators is higher than the variance explained 
by the latent factor (Hair et al., 2010). 
 Higher item-scale correlations (Pearson’s correlation between score on an individual item 
in a sub-domain with the total score on the underlying sub-domain) indicate that expected items 
in the same sub-domains correlate strongly with each other.  This approach of establishing 
convergent validity has been used by previous studies (Khanna, Jariwala, & West-Strum, 2015).  
Item-scale correlations of 0.1-0.29 were considered small, 0.3-0.49 as moderate, and ≥ 0.45 was 
considered to be suggestive of strong (Cohen, 1988).  It was hypothesized that the correlation 
between an item and its underlying sub-domain will be higher than with other sub-domains.  A 
strong correlation of the items which belong to the GH, PF, RP, and BP sub-domains with PCS 
was hypothesized. Similarly, a strong correlation between items representing the RE, MH, VT, 
SF sub-domains with MCS summary scale score was hypothesized.   
Discriminant validity.  Discriminant validity is the extent to which a construct is distinct from 
other constructs.  The following methods were used to assess the discriminant validity of the 
physical and mental health dimensions of the SF-12v2. 
 First, after freeing all factor loadings for the items on the SF-12v2, the correlation 
between the LPF and LMF was fixed to one in the 2-factor model.  Following this, it was 
assessed whether the fit of the 2-factor model was significantly different from the 1-factor 
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model.  A significant difference in the model fit between the two models was suggestive of 
discriminant validity.  This is not a very strong test of discriminant validity because even a very 
correlation between the two constructs (≥ 0.90 or higher but not exactly 1) would indicate 
adequate discriminant validity.   
 Second, the difference between the AVE for each latent construct and the square of the 
correlation estimate between the two constructs was calculated.  A positive difference (i.e., the 
two AVE’s exceed the sum of the square of the correlation between LMF and LPF) is indicative 
of the fact that the latent construct explains a higher proportion of the variance in its indicator 
items as compared to the variance shared with another latent construct, suggesting discriminant 
validity (Fornell & Larcker, 1981). 
 Third, lower item-to-other scale correlations (≤ 0.40) were suggestive of adequate 
discriminant validity.  The reasoning behind this technique was that items from different 
domains should have low or no correlations with each other.  It was hypothesized that the 
correlation between an item and other sub-domains will be weaker than with its underlying sub-
domain.  A weak correlation of the items which belong to the GH, PF, RP, and BP sub-domains 
with MCS was hypothesized. Similarly, a weak correlation between items representing the RE, 
MH, VT, SF sub-domains with PCS summary scale score was hypothesized. 
Known-groups validity.  Known-groups validity is the ability of an instrument to differentiate 
among individuals who have levels of disease severity.  One-way ANOVA was used to compare 
the PCS and MCS from the SF-12v2 across hemophilia patients with different symptom severity 
levels obtained using the PGI-S. 
Internal consistency reliability. In order to evaluate the internal consistency reliability of the 
PCS and MCS for the SF-12v2, Cronbach’s alpha (α) was calculated.  An α ≥ 0.70 was 
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considered to be suggestive of adequate internal consistency reliability for the PCS and the MCS 
(Okonkwo et al., 2010). 
Floor and ceiling effects. In order to assess the floor and ceiling effects of the SF-12v2, the 
percentage of adults with hemophilia with the least possible and the maximum possible PCS and 
MCS were determined.  Floor and ceiling effects were considered to be present if more than 20% 
of the respondents received the lowest or the highest possible PCS or MCS summary scale score 
(Holmes & Shea, 1997; Khanna et al., 2015). 
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RESULTS 
Socio-demographic characteristics 
The final study sample consisted of 218 adults with hemophilia (Table 2.1).  The majority 
of the study population included patients with hemophilia A (77.5%), males (79.5%), and 
Caucasians (68.5%).  169 (77.5%) of these patients were recruited using an online panel of 
hemophilia patients (i.e., Rare Patient Voice), 44 (20.2%) were recruited using a Facebook 
community of hemophilia patients (i.e., Hemo Friends), and 6 (2.3%) were recruited at the 
UMMC HTC. The mean age of the study sample was 35.45 (12.3) years.  Patients also 
commonly suffered from comorbidities such as hepatitis C (36.5%) and depression (38.4%).      
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Table 0.1: Demographic and clinical characteristics the study sample 
Characteristics N (%) 
Diagnosis   
   Hemophilia A 169 (77.5) 
   Hemophilia B 49 (22.5) 
Gender   
  Male 174 (79.5) 
  Female 24 (11.0) 
Age, mean (sd) 35.45 (12.3) 
Race/Ethnicity   
  White/Caucasian 150 (68.5) 
  Other* 47 (21.5) 
Marital Status   
  Never Married 66 (30.1) 
  Married 98 (44.7) 
  Other† 34 (20.1) 
Education level   
  Less than high school 9 (4.1) 
  High school or technical school 30 (13.7) 
  College degree 128 (58.4) 
  Masters degree 17 (7.8) 
  Doctoral degree 6 (2.7) 
  Professional degree 8 (3.7) 
Employment Status   
  Employed/self–employed full time  103 (47.0) 
  Employed part–time 23 (10.5) 
  On disability 16 (7.3) 
  Other‡ 56 (25.6) 
Region of the country   
  Northeast 46 (21.0) 
  Midwest 40 (18.3) 
  South 54 (24.7) 
  West 58 (26.5) 
Health Insurance   
  Public 61 (27.9) 
  Private 113 (51.6) 
  Both  6 (2.7) 
  None 18 (8.2) 
Disease severity   
  Mild (5%-40% clotting factor activity) 42 (19.2) 
  Moderate (1%-5% clotting factor activity) 25 (11.4) 
  Severe (>1% clotting factor activity) 127 (58.0) 
  Not sure 3 (1.4) 
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Symptom Severity   
  No symptoms 31 (14.2) 
  Mild symptoms 67 (30.6) 
  Moderate symptoms 61 (27.9) 
  Severe symptoms 39 (17.8) 
Treatment Regimen   
  Always received on prophylaxis therapy 121 (55.3) 
  Received both prophylaxis and on-demand therapy  31 (14.2) 
  Always received on on-demand therapy 45 (20.5) 
Number of bleeding episodes in the past year, mean (sd) 11.69 (19.1) 
Hemophilia-related surgery    
  Yes 73 (33.3) 
  No 124 (56.6) 
Number of hemophilia-related surgeries in the past year, mean (sd) 
3.64 (3.9) 
Comorbidities   
  Hepatitis C 80 (36.5) 
  HIVˠ 26 (11.9) 
  Depression 84 (38.4) 
  Inhibitors to clotting factor 41 (18.7) 
Annual number of hemophilia-related visits, mean (sd)   
  Hemophilia Treatment Center (HTC) 2.23 (3.1) 
  Hematologist outside a HTC 0.83 (1.8) 
  Primary Care Practitioner 2.42 (4.2) 
Note: SD, standard deviation; Frequencies for each demographic characteristic may 
not add up to the total sample size due to the presence of missing data. 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, Native 
Hawaiian/Other Pacific Islander, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with partner 
‡Other includes retired, home–maker, student, seeking work, etc. 
ˠHIV - Human Immuno Deficiency Virus. 
Patient recruitment – 169 (77.5%) from Rare Patient Voice, 44 (20.2%) from Hemo 
Friends, and 6 (2.3%) from UMMC HTC. 
 
Item distribution and quality 
Table 2.2 shows the mean scores, and skewness and kurtosis coefficients on a per-item 
basis for the SF-12v2.  The skewness and kurtosis coefficients for all items on the SF-12v2 were 
found to be within a range of -1.00 and 0.63.  Based on these ranges, the data appear to be 
normally distributed.  The mean PCS was 43.68 (±10.19) and the mean MCS was found to be 
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46.48 (±10.09) among adults with hemophilia.  The mean score for each of the eight SF-12v2 
domains as well as the PCS and the MCS were lower than the norm score for the general healthy 
US population.  The distribution of the PCS and MCS scores across the study sample can be 
found in Figure 2.1 and 2.2 below.  This indicated that adults with hemophilia had a worse 
overall HRQOL as compared to the US norm population.  There was no missing data for any of 
the SF-12v2 items.    
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Table 0.2: Item-level and domain-level characteristics for the SF-12v2 among adults with hemophilia 
Items  N Missing  Mean (SD) Skewness Kurtosis 
        Statistic Std. error Statistic Std. error 
Health in general (GH01) 218 0 2.89 (0.94) 0.28 0.164 -0.22 0.327 
Limitation in moderate 
activities (PF02) 218 0 2.25 (0.69) -0.36 0.164 -0.86 0.327 
Limitation in climbing stairs 
(PF03) 218 0 2.17 (0.78) -0.3 0.164 -1.00 0.327 
Accomplished less due to 
physical health (RP04) 218 0 3.31 (1.28) -0.24 0.164 -0.88 0.327 
Limited in health due to 
physical health (RP05) 218 0 3.25 (1.26) -0.12 0.164 -0.96 0.327 
Pain interfered with work 
(BP08) 218 0 2.91 (1.18) 0.09 0.164 -0.94 0.327 
Have a lot of energy (VT10) 218 0 3.09 (1.03) 0.1 0.164 -0.50 0.327 
Physical health or emotional 
problems interfered with 
social activities (SF12) 218 0 3.56 (1.13) -0.43 0.164 -0.42 0.327 
Accomplished less due to 
emotional problems (RE06) 218 0 3.54 (1.30) -0.46 0.164 -0.95 0.327 
Less careful due to emotional 
problems (RE07) 218 0 3.8 (1.20) -0.63 0.164 -0.62 0.327 
Felt calm and peaceful 
(MH09) 218 0 2.62 (0.98) 0.42 0.164 -0.36 0.327 
Felt downhearted and 
depressed (MH11) 218 0 3.65 (1.10) -0.55 0.164 -0.47 0.327 
Physical Component Score 
(PCS) 218 0 43.68 (10.19) -0.62 0.164 0.61 0.327 
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Mental Component Score 
(MCS) 218 0 46.48 (10.09) -0.72 0.165 1.23 0.328 
                Responses to the items on the SF-12v2were measured using 3 or 5-point response scales 
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Figure 0.1: Distribution of SF-12v2 Physical Component Score 
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Figure 0.2: Distribution of SF-12v2 Mental Component Score 
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Factorial validity. Figures 2.3, 2.4, and 2.5 depict the three SF-12v2 factor models which were 
tested in order to examine the factorial validity of the instrument among adults with hemophilia. 
The model fit indices for the three models can be found in Table 2.3.  The single factor model 
where all items loaded onto a single latent HRQOL factor had a poor fit (Chi-square [df] = 
531.807 [53]; CFI = 0.896; TLI = 0.870; RMSEA [90% CI] = 0.203 [0.188-0.209]; WRMR = 
2.011).  The two-factor model tested by Okonkwo et al. (2010) had a moderate-mediocre fit 
(Chi-square [df] =340.418 [49]; CFI = 0.936; TLI = 0.914; RMSEA [90% CI] = 0.165 [0.149-
0.182]; WRMR = 1.409).  The two-factor model based on the approach used by Maurischat et al. 
(2008) had the best fit among the three models which were tested (Chi-square [df] = 270.183 
[49]; CFI = 0.952; TLI = 0.935; RMSEA [90% CI] = 0.144 [0.127-0.162]; WRMR = 1.250).  
Based on the modification indices, the error terms for items 9 and 10 (i.e., MH09 and VT10) 
were correlated in model 3 in addition to the corrected residuals already specified in the 
Maurischat et al. (2008) model.  This improved the model fit of the final model significantly 
(Chi-square [df] = 172.778 [48]; CFI = 0.972; TLI = 0.962; RMSEA [90% CI] = 0.109 [0.092-
0.127]; WRMR = 0.947).    
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Table 0.3: Summary of model fit indices for the SF-12v2 confirmatory factor models 
Fit Statistics  Model 1 Model 2 Model 3 
      
Chi-square (df) 531.807 (53) 340.418 (49) 172.778 (48) 
CFI 0.896 0.936 0.972 
TLI 0.870 0.914 0.962 
RMSEA (90% CI) 0.203 (0.188 - 0.219) 0.165 (0.149 - 0.182) 0.109 (0.092 - 0.127) 
WRMR 2.011 1.409 0.947 
Model 1 - All items load onto a single latent health-related quality of life factor;                                                                          
Model 2 - SF-12 CFA model based on Okonkwo et al. (2010);                                                                                                       
Model 3 - SF-12 CFA Model based on Maurischat et al. (2008).                                                                                                     
Note: df, degrees of freedom; CFI, Comparative Fit Index; TLI, Tucker-Lewis Index; RMSEA, Root Mean Square 
Error of Approximation; WRMR, Weighted Root Mean Square Residual; CI, Confidence Interval. 
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Figure 0.3: Single Factor Model for the SF-12v2 
 
 
 
 
 
  
 
5
4
 
Figure 0.4: Two Factor Model for the SF-12v2 based on Okonokwo et al. (2010) 
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Figure 0.5: Two Factor Model for the SF-12v2 based on Maurischat et al. (2008) 
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Table 0.4: Standardized factor loadings for the final two factor model of 
HRQOL for the SF-12v2 among adults with hemophilia 
 
Items 
Estimateˠ 
(SE) 
    
Latent Physical Factor    
Health in general (GH01) -0.734 (0.040) 
Limitation in moderate activities (PF02) 0.848 (0.028) 
Limitation in climbing stairs (PF03) 0.758 (0.038) 
Accomplished less due to physical health (RP04) 0.842 (0.025) 
Limited in health due to physical health (RP05) 0.831 (0.026) 
Pain interfered with work (BP08) -0.785 (0.030) 
    
Latent Mental Factor   
Accomplished less due to emotional problems (RE06) 0.766 (0.044) 
Less careful due to emotional problems (RE07) 0.726 (0.037) 
Felt calm and peaceful (MH09) -0.443 (0.054) 
Have a lot of energy (VT10) -0.575 (0.048) 
Felt downhearted and depressed (MH11) 0.627 (0.040) 
Physical health or emotional problems interfered with social 
activities (SF12) 0.878 (0.028) 
    
Latent Factor Correlation   
Latent Physical Factor with Latent Mental Factor 0.829 (0.039) 
    
Correlated Residuals   
Item 2 with Item 3 0.355 (0.091) 
Item 4 with Item 5 0.591 (0.047) 
Item 6 with Item 7 0.627 (0.041) 
Item 9 with Item 10 0.552 (0.054) 
Item 9 with Item 11 -0.323 (0.049) 
Items with negative factor loadings represent those SF-12 questions on 
which higher scores indicated poorer health status whereas items with 
positive factor loadings represent the SF-12 questions on which higher 
scores reflected better health status 
ˠAll factor loadings were significant at α = 0.05 
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Convergent validity.  The standardized factor loadings for the final study model have been 
reported in table 2.4 above.  All factor loadings were statistically significant at α = 0.05.  Most 
factor loadings (except item 9 on LMF) were greater than 0.5.  The AVE for the LPF was found 
to be 0.64 and the AVE for the LMF was 0.47.  Table 2.5 depicts the item-scale correlation 
matrix. The correlation between the eight subdomains and their underlying item(s) were strong 
and statistically significant.  Items comprising the PF, RP, GH, and BP subdomains had a strong 
and statistically significant correlation with the PCS.  While RE, MH, VT, SF items were 
strongly correlated with the MCS summary scale score.  Overall the standardized factor loadings, 
AVE for each latent factor, and item-scale correlations suggested acceptable convergent validity 
for the SF-12v2 among adults with hemophilia. 
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Table 0.5: Item-scale correlations for the SF-12v2 among adults with hemophilia 
  GH PF RP RE BP MH VT SF PCS MCS 
GH            
  GH01 -.990** -.589** -.572** -.291** -.455** -.322** -.502** -.414** -.710** -.256** 
PF            
  PF02 .521** .893** .656** .477** .555** .326** .339** .576** .758** .304** 
  PF03 .540** .918** .587** .291** .514** .285** .338** .444** .791** .137* 
RP            
  RP04 .537** .646** .956** .561** .600** .306** .302** .563** .760** .341** 
  RP05 .543** .659** .955** .522** .575** .315** .327** .539** .769** .304** 
RE            
  RE06 .255** .392** .569** .945** .431** .460** .300** .592** .282** .741** 
  RE07 .275** .394** .495** .936** .457** .450** .287** .546** .258** .717** 
BP            
  BP08 -.454** -.588** -.615** -.472** 1.000** -.376** -.391** -.577** -.736** -.350** 
MH            
  
MH09 
-.364** -.254** -.203** -.278** -.342** -.834** -.599** -.364** -.141* -.627** 
  
MH11 
.173* .318** .346** .538** .303** .872** .313** .490** .095 .761** 
VT            
  VT10 -.485** -.374** -.329** -.312** -.391** -.524** 1.000** -.425** -.371** -.592** 
SF            
  SF12 .409** .561** .580** .609** .577** .496** .425** 1.000** .512** .671** 
Note: GH, general health; PF, physical functioning; RP, role physical; VT, vitality; SF, social functioning; 
RE, role emotional; MH, mental health; PCS, Physical Component Summary; MCS, Mental Component 
Summary 
**. Correlation is significant at the 0.01 level. 
*. Correlation is significant at the 0.05 level. 
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Discriminant validity.  Three separate tests were employed in order to examine the discriminant 
validity of the SF-12v2.  First, the fit of the two factor model (Figure 2.5) was compared to that 
of a model where the correlation between LPF and LMF was fixed to one.  The test yielded a 
significant difference in the chi-square value (Chi-square [df] = 18.686 [1]; p<0.0001) which was 
suggestive of adequate discriminant validity (Hair et al., 2010).  Second, the difference between 
the AVE for each latent factor and the square of the latent factor correlation was not found to be 
positive for either the LPF or the LMF.  A non-positive difference was suggestive of lack of 
adequate discriminant validity (Hair et al., 2010).  Last, items comprising the PF, RP, GH, and 
BP subdomains had a weak correlation with the MCS summary scale score.  While RE, MH, VT, 
SF items had a weak to moderate correlation with the PCS summary scale score.  Overall the SF-
12v2 was found to have acceptable discriminant validity among adults with hemophilia.  
Known-groups validity.  The ability of the SF-12v2 to discriminate between hemophilia patients 
with no symptoms, mild symptoms, moderate symptoms, and severe symptoms was assessed 
using a one-way ANOVA (Table 2.6).  Differences in PCS and MCS scores between individual 
groups were assessed using post-hoc Tukey’s honestly significant difference (HSD) tests.  The 
mean PCS (50.10 vs 47.39 vs 40.79 vs 35.24; p<0.0001) and MCS (50.61 vs 46.80 vs 46.96 vs 
42.29; p = 0.007) summary scale scores were significantly different across the four symptom 
severity levels.  A definite gradation was observed in terms of the PCS and MCS with increasing 
levels of symptom severity on the PGI-S.  Specifically, the mean PCS score for patients with no 
symptoms over the past 4 weeks (50.10) was significantly higher than the score for patients with 
moderate (40.79) or severe (35.24) symptoms.  Patients with mild symptoms (47.39) had a 
significantly higher PCS score as compared to those with moderate (40.79) or severe (35.24) 
symptoms. The PCS summary scale score for those with moderate symptoms (40.79) was 
 60 
 
significantly greater than for those with severe symptoms (35.24).  Finally, patients with no 
symptoms (50.69) had a significantly higher MCS summary scale score as compared to those 
with severe symptoms (42.29). 
 The SF-12v2 was not able to discriminate across hemophilia severity levels based on 
self-reported blood clotting factor activity level.    
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Table 0.6: Known-groups validity for the SF-12v2 components among adults with hemophilia 
Component 
No 
symptoms  
(N = 31) 
Mild 
Symptoms 
(N = 67) 
Moderate 
Symptoms           
(N = 61) 
Severe 
Symptoms     
(N = 39)   
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) p-value 
Physical 
Component 
Summary Score 
(PCS) 50.10 (7.92)ˠ 47.39 (8.25)* 40.79 (8.59)ˠ*¥ 35.24 (10.78)ˠ*¥ <0.0001 
Mental 
Component 
Summary Score 
(MCS) 50.61 (8.23)√ 46.80 (9.53) 46.96 (9.27) 42.29 (12.28)√ 0.007 
ˠSignificant difference in mean PCS scores between group 1 as compared to group 3 and group 4 
at alpha less than or equal to .05 based on Tukey's HSD (Honestly Significant Difference) test.                                     
*Significant difference in PCS scores between group 2 as compared to group 3 and group 4 at 
alpha less than or equal to .05 based on Tukey's HSD test.                                                                                                       
¥Significant difference in PCS scores between group 3 and group 4 at alpha less than or equal to 
.05 based on Tukey's HSD test.                                                                                                                                                    
√Significant difference in mean MCS scores between group 1 and group 4 at alpha less than or 
equal to .05 based on Tukey's HSD test. 
Note: SD, standard deviation p-values are based on a one-way analysis of variance  
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Internal Consistency Reliability.  The internal consistency reliability for the SF-12v2 was found 
to be satisfactory with the Cronbach’s alpha value of 0.848 for PCS and 0.785 for MCS (Table 
2.7).   
Table 0.7: Reliability analysis for the SF-12v2 components among adults with hemophilia 
Component Mean (SD) 
Cronbach's 
alpha 
No. of 
items 
Physical 
Component 43.92 (3.02) 0.848 6 
Mental 
Component 45.53 (2.63) 0.785 6 
 
Floor and ceiling effects.  Less than 20% of the study sample received the lowest or highest 
possible PCS or MCS summary scale score which was indicative of the absence of floor and 
ceiling effects.  The minimum and maximum PCS score for the study sample was 16.95 and 
67.63 respectively.  The minimum and maximum MCS score was 15.75 and 68.91 respectively.  
The minimum and maximum PCS score for the general US population as per the SF-12 scoring 
manual is 4.92 and 69.24 respectively.  While the minimum and maximum MCS score for the 
US norm population   was 8.14 and 73.24 respectively (Ware, Kosinski, Turner-Bowker, 
Gandek, 2005).  Therefore none of the respondents from our study sample received the lowest or 
highest possible score as per the general US population. 
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DISCUSSION 
Hemophilia is a rare genetic blood coagulation disorder which impact the physical, 
mental, and social aspects of the life of an individual.  As HRQOL continues to evolve as a key 
health outcomes endpoint among patients with hemophilia, so does the need for 
psychometrically-sound generic instruments which measure HRQOL.  Such instruments not only 
allow one to ascertain the burden of hemophilia on patient HRQOL, but also compare their 
HRQOL to the healthy US population and across subgroups of individuals suffering from other 
diseases.  The current study assessed the validity (factorial, convergent, discriminant, and 
known-groups) and internal consistency reliability of the SF-12v2, a generic measure of 
HRQOL, among adults with hemophilia. 
  The mean PCS for the study population was found to be 43.67 (±10.67) and the mean 
MCS was 46.48 (±10.09).  Thus adults with hemophilia had worse PCS and MCS scores as 
compared to the US norm population (PCS and MCS = 50.0 (±10.00)).  Adults with hemophilia 
had the lowest mean score on the two physical functioning items (Items 2 and 3).  This is 
understandable because hemophilia patients experience repeated bleeding into joints and large 
muscle groups.  These prolonged bleeding episodes eventually result in hemophilic arthropathy, 
chronic pain, and reduction in the range of joint motion leading to difficulties with moderate 
physical activities such as moving a table, pushing a vacuum cleaner or climbing several flights 
of stairs.
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Factorial validity of the SF-12v2 was tested by examining the model fit indices across three 
different models.  The two-factor model based on the approach adopted by Maurischat and 
colleagues (2006, 2008) was found to be the best fitting model in this population.  Previous 
studies have also conceptualized the SF-12v2 as a two factor model where items related to the 
GH, PF, RP, BP subdomains loaded onto a LPF while items related to the RE, MH, VT, SF 
subdomains loaded onto a LMF and the error covariance for items which belonged to the same 
subdomain (PF, RP, RE, and MH) were correlated (Maurischat et al., 2008; McBride, Adamson, 
Bunting, & McCann, 2009).  Items which belonged to the same subdomain were expected to 
have commonality which warranted the correlation of the residuals for these items.  Previous 
studies have reported that a similar two-factor model for the SF-12v2 was found to have 
acceptable fit among patients with inflammatory rheumatic disease (Maurischat et al., 2006), and 
diabetes mellitus (Maurischat et al., 2008).  In the current study based on the modification 
indices, minor modifications driven by data were made where the error covariance for item 9 
(felt calm and peaceful) and item 10 (had a lot of energy).  Residuals for these items on the SF-
12 have been previously shown to be correlated by McBride et al. (2009) in a sample of 
diagnostic orphans and by Fleishman and Lawrence (2003) in a population of non-
institutionalized US civilians (Fleishman & Lawrence, 2003; McBride et al., 2009). 
 The SF-12v2 was found to have good convergent validity among adults with hemophilia.  
Considering the best fitting model, the size of each factor loading was greater than 0.5 indicating 
that the latent factor explained at least 50% of the variance in each observed indicator.  AVE for 
both latent factors was close to 0.5 which was indicative of the fact that the latent factors 
explained a higher proportion of the variance in the observed indicators than the error variance 
which remained unexplained.  We did not find evidence of adequate discriminant validity of the 
 65 
 
SF-12v2 among adults with hemophilia.  This was primarily because of the high correlation 
between the LPF and the LMF as compared to previous studies (Okonokwo et al., 2010; 
Maurischat et al., 2006; Maurischat et al., 2008).  Future studies must examine and assess the 
reasons for this correlation between the LPF and LMF.  Finally, individual items were more 
strongly correlated with the subdomain they represented as compared to other subdomains.  
Items which belonged to the GH, PF, RP, BP subdomains were strongly correlated with PCS and 
weakly correlated with MCS.  Also, the RE, MH, VT, and SF items were strongly correlated 
with MCS and weakly (or moderately in case of item 12) correlated with PCS.  Similar results 
have been reported by previous studies among adults with autism (Khanna et al., 2015). 
 The results of the current study lend support to the known-groups validity of the SF-12v2 
in terms of its ability to discriminate across different symptom severity levels among adults with 
hemophilia.  Mean PCS and MCS were found to be significantly different across the four 
symptom severity groups.  Additionally with an increase in the symptom severity level mean 
PCS summary scale scores were found to decrease significantly.  A similar distinct downward 
trend was not seen in case of mean MCS with an increase in symptom severity.  The mean MCS 
for the moderate symptom severity group was greater than the MCS for the mild symptom 
severity group.  However, this increase was not found to be statistically significant.  The SF-
12v2 was not able to discriminate across hemophilia severity levels based on self-reported blood 
clotting factor activity level.  This may be because 58% of the study sample was classified as 
having severe hemophilia (i.e., clotting factor activity level less than 1%).  There may not have 
been enough sample size in the mild and moderate hemophilia groups in order to detect 
differences in PCS and MCS even if there were any. 
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 The internal consistency reliability of the PCS and MCS summary scales was found to be 
good.  Also, PCS and MCS scale scores did not indicate the presence of any floor or ceiling 
effects and therefore the SF-12v2 was considered to be sensitive in capturing the variation in 
HRQOL among adults with hemophilia. 
 The results of the current study must be interpreted in the light of certain limitations.  The 
cross-sectional nature of the study precluded us from assessing the predictive validity as well as 
test-retest reliability of the SF-12v2 in the study population.  Future studies should adopt a 
longitudinal design in order to explore these aspects of the psychometric profile of the SF-12v2.  
Adults with hemophilia who participated in this study are likely to have higher physical 
functioning because of their ability to participate in survey research.  This may limit the 
generalizability of the study results. 
 This was the first US-based study to psychometrically validate a generic measure of 
HRQOL among adults with hemophilia.  Considering that hemophilia is a rare genetic disorder, 
most previous published reports have employed smaller sample sizes.  The Hemophilia 
Utilization Group Study (HUGS) employed a larger sample size of hemophilia patients as 
compared to the current study however all patients were recruited at six HTC’s across the 
country.  Patients treated in a non-HTC setting were not included in the HUGS.  To the best of 
our knowledge, this is the first US based study to capture the HRQOL of a large population of 
adults with hemophilia who are treated in a HTC and non-HTC setting.  For the current study, 
adults with hemophilia were recruited using multiple sources including an online rare disease 
patient panel, a private Facebook community of hemophilia patients, and at a HTC in the south 
eastern region of the country.  The study sample included an even distribution of patients from 
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all regions of the country which ensures the generalizability of the study results to most adults 
with hemophilia in the US. 
 This study provides evidence about the acceptable psychometric properties of the SF-
12v2 among adults with hemophilia in the US.  The SF-12v2 was found to be a valid and reliable 
generic measure of HRQOL among adults with hemophilia.  The scale demonstrated adequate 
factorial, convergent, and known-groups validity.  The scale was found to have adequate internal 
consistency reliability and no evidence of the presence of a floor or ceiling effect was found.  
Overall, the results provide basis for the future use of the SF-12v2 among adults with hemophilia 
and incorporating the HRQOL information obtained from these studies into health policy and 
clinical decision making.  
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CHAPTER III: ASSESSING MEASUREMENT INVARIANCE OF THE SHORT 
FORM – 12 (SF-12) AMONG ADULTS WITH HEMOPHILIA IN THE UNITED 
STATES 
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INTRODUCTION 
Hemophilia is a chronic blood coagulation disorder which is caused by the genetic deficiency of 
clotting factor VIII or IX in the blood plasma.  Patients with hemophilia suffer from bleeding 
into large joints and muscle groups.  This causes severe pain, loss of range of joint motion, and 
could eventually lead to chronic arthropathy (National Hemophilia Foundation, 2014).  Health-
related quality of life (HRQOL) is considered to be a very important indicator of outcomes 
among patients with such chronic diseases because complete recovery may not be possible 
(Okonkwo, Roth, Pulley, & Howard, 2010).  
Assessment of HRQOL often involves comparisons of health status among different 
subgroups of patients.  However, before carrying out such planned comparisons, it is essential 
that the researcher is confident that the items comprising the HRQOL measure operate 
equivalently across these different patient subgroups.  In other words, when testing differences 
between groups of patients using a well-established measure of HRQOL (such as the Short 
Form-12 Health Survey [SF-12]), it is fundamental that members of different groups assign the 
same meaning to questionnaire items. Thus patients at the same level of the underlying latent 
construct (HRQOL in this case) must respond to an observed item in the same way and patient 
responses must not be influenced by patient characteristics (such as age, gender).  If it can be 
shown that patient characteristics do not affect the psychometric properties of the observed 
questionnaire items, then the assumption of measurement invariance is said to be met.  If the 
assumption of measurement invariance holds, then the observed differences in HRQOL among 
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groups defining the study populations are true differences and not measurement artifacts (Brown, 
2015).  For example, women are more likely to endorse items about crying rather than men on 
the Center for Epidemiological Studies Depression Scale (CES-D) given the same underlying 
level of depression.  Thus even though a gender difference exists in terms of crying, depression 
scores for women, as compared to men, may be inflated due to gender bias in the measurement 
of depression (Pollard, Johnston, & Dixon, 2013). 
Testing the assumption of measurement invariance commonly involves comparisons of 
the measurement model (i.e., observed indicators, factor loadings, indicator intercepts, and 
indicator variances) and the structural parameters (i.e., latent factor variances, covariances, and 
latent means) of the model across population subgroups. The former evaluations are called tests 
of measurement invariance while the latter comparisons are known as tests of population 
heterogeneity. Several analytical techniques including item response theory (IRT) and structural 
equation modeling (SEM) can be employed to test the assumption of measurement invariance.  
Within the framework of SEM, multi-group CFA and MIMIC (multiple indicators, multiple 
causes) modeling are commonly used approaches for testing the assumption of measurement 
invariance (King-Kallimanis et al., 2012).  In cross-sectional research, the multi-group CFA 
approach is used very commonly because it allows the examination of all aspects of 
measurement invariance and population heterogeneity (i.e., factor loadings, indicator intercepts, 
indicator variances, factor variances, factor covariances, and latent means).  However, multi-
group CFA has restrictive sample size requirements because the sample must be split by group 
membership.  In MIMIC modeling, the potential violator of invariance (e.g. age, gender) is 
dummy coded and included in the model along with other indicators as a single exogenous 
variable.  The MIMIC approach affords greater parsimony (as fewer parameters are freely 
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estimated), is relatively easier to implement, and has less stringent sample size requirements. 
However, a key limitation associated with MIMIC modeling, as opposed to multi-group CFA, is 
the fact that it can only examine two potential sources of invariance (i.e., indicator intercepts, 
latent means). Therefore the multi-group CFA approach is generally preferred despite its larger 
sample size requirements (Brown, 2015). 
Establishing the reliability and validity of a scale in a particular population does not 
ensure that the instrument will not violate the measurement invariance assumption. The SF-12v2 
is a commonly used generic measure of HRQOL (Ware, Kosinski, & Keller, 1996).  It measures 
eight dimensions of patient health (i.e., physical functioning, role-physical, bodily pain, general 
health, vitality social-functioning, role-emotional, and mental health) which can be aggregated 
into the physical component summary score (PCS) and the mental component summary score 
(MCS).  Demographic variations in SF-12 scores have been assessed by previous studies in order 
to determine whether these are true differences or an indication of measurement invariance. 
Okonkwo and colleagues (2010) found item factor loadings on the SF-12v2 to be largely 
invariant across patients with and without a history of stroke. Fleishman and Lawrence tested the 
assumption of measurement invariance for the SF-12 in a national sample of adults in the United 
States (US) (Fleishman & Lawrence, 2003).  Age was found to be a source of measurement non-
invariance for items which load onto the mental health component.  The authors also suggested 
that differences in education, age, and gender must be controlled for when assessing group 
differences in PCS and MCS scores on the SF-12.      
Although the SF-12v2 has been previously utilized to assess HRQOL among patients 
with hemophilia (Duncan, Shapiro, Ye, Epstein, & Luo, 2012; Poon, Pope, & Tarlov, 2013), the 
assumption of measurement invariance has not been tested with respect to key predictors of 
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HRQOL in this population. Most studies in the literature have suggested that patient age, disease 
severity, and treatment regimen (i.e. prophylaxis or episodic care) are three of the most 
significant predictors of HRQOL among patients with hemophilia A and B (Brown, Lee, Joshi, 
& Pashos, 2009; Gringeri et al., 2004; Miners et al., 1999; Royal et al., 2002). However before 
assessing differences in HRQOL based on patient age, disease severity, and treatment regimen, it 
is essential to examine measurement bias in HRQOL with respect to these variables.   
The current study will examine whether HRQOL measured using the SF-12v2 is 
invariant with respect to age, disease severity, and treatment regimen among adult diagnosed 
with hemophilia in the US.  This will not only help us obtain deeper insight into the 
psychometric properties of the SF-12v2 but also better our understanding of the construct of 
HRQOL among patients with rare genetic blood coagulation disorders.  
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METHODS 
Study Design 
This study employed a cross-sectional design by means of an online self-administered 
survey designed using Qualtrics (Qualtrics Inc, Provo, UT). Institutional Review Board (IRB) 
approval was for the current study obtained from the University of Mississippi IRB under the 
exempt status. 
Study population  
The study sample for the current study included patients with hemophilia A or B who 
were greater than 18 years of age.  Patients with other blood coagulation disorders such as Von 
Willebrand’s disease were not included in the study population.  Data for the current study were 
collected using a panel of hemophilia patients, provided by a market research vendor company 
called Rare Patient Voice.  In order to meet the sample size requirements for multi-group CFA, 
patients with hemophilia were also recruited at the University of Mississippi Medical Center 
(UMMC) hemophilia treatment center (HTC) as well as through a private Facebook community 
called Hemo Friends. 
Study procedures 
The current study was a part of a larger study which aimed at assessing the psychosocial 
predictors of HRQOL among adults with hemophilia in the US. Only information relevant to the 
current study has been reported in this section. Initially an email explaining the nature and scope 
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of the research was sent out to potential study participants. This email also contained a URL link 
to the study survey. Data collection was open from October 31, 2015 to February 1, 2016. All 
respondents were provided with $10 Amazon gift cards as an incentive to participate in the 
study. 
Study Measures 
SF-12 Health Survey Version 2 (SF-12v2).  The SF-12v2 includes 12 items and was developed 
to be a much shorter, yet valid, alternative to the SF-36 for use in specific populations. The SF-
12v2 has a 4 week recall period (Ware et al., 1996). The SF-12v2 has 8 domains summarized in 
Table 1.  
Table 0.1.  SF-12v2® Domains and Items 
Domain 
Domain 
Abbreviation 
Total Number of Items in 
Domain 
Items Specific to 
Domain 
Physical 
functioning  
PF 2 
Items 2 and 3 
Role physical RP 2 Items 4 and 5 
Bodily pain  BP 1 Item 8 
General health  GH 1 Item 1 
Vitality  VT 1 Item 10 
Social 
functioning  
SF 1 
Item 12 
Role emotional  RE 2 Items 6 and 7 
Mental health  MH 2 Items 9 and 11 
Items on the SF-12v2 use either a 3- or a 5-point response format. The SF-12v2 is used to 
compute two general summary measures of HRQOL, Mental Component Summary score (MCS) 
and Physical Component Summary score (PCS), derived from the 8 domain scores with higher 
scores indicating better health status. The component and domain scores are transformed to a 0 – 
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100 scale and subsequently transformed to norm based scores with a mean of 50 and a standard 
deviation of 10 in the general US population. The software from Optum® was be used to 
calculate the scores for the SF-12v2 domains and components (PCS and MCS).  
Patient Global Impression of Severity (PGI-S). The PGI-S is a single self-reported item that asks 
respondents to rate the severity of their condition. In this study, the PGI-S was specifically worded as 
“When thinking about all of the hemophilia-related symptoms that you may have experienced during the 
past 7 days, please circle the one number that best describes how your symptoms overall have been; on a 
4-point scale scored as: (1) “no symptoms”, (2) “mild”, (3) “moderate”, or (4) “severe”. The construct 
validity of the PGI-S has been previously assessed in male subjects with lower urinary tract symptoms 
secondary to benign prostatic hyperplasia and women with stress urinary incontinence (Viktrup, Hayes, 
Wang, & Shen, 2012; Yalcin & Bump, 2003).  
Demographic and health information.  The following socio-demographic and clinical 
characteristics: (1) age, (2) race/ethnicity, (3) education status, (4) marital status, (5) occupation 
status, (6) disease severity, (7) monthly bleeding frequency, (8) type of treatment, and (9) 
hemophilia-related comorbidities. 
Statistical Analysis 
 Demographic and clinical comorbidity related variables were summarized using 
descriptive statistics. Frequencies and percentages were calculated for categorical variables while 
means and standard deviations were determined for continuous variables.   
Step 1: Establishing a measurement model for the SF-12v2 
The two-factor model of the SF-12v2 where items related to the GH, PF, RP, BP 
subdomains loaded onto a latent physical factor (LPF), items related to the RE, MH, VT, SF 
subdomains loaded onto a latent mental factor (LMF).  The residual for each of the two PF, RP, 
 81 
 
RE, and MH items were correlated.  The LPF and LMF were allowed to freely correlate as well 
(Maurischat, Herschbach, Peters, & Bullinger, 2008; McBride, Adamson, Bunting, & McCann, 
2009).  The final measurement model for the SF-12v2 can be found in figure 3.1 below.  Details 
about the methodology adopted for establishing this measurement model can be found in chapter 
2 of this dissertation.   
Step 2: Testing measurement invariance with respect to exogenous variables (i.e., age, 
symptom severity, and treatment regimen) 
Multi-group CFA was used for testing the assumption of measurement invariance across 
patients belonging to different age groups (18-34 versus greater than 34 years of age), disease 
severity levels (no/mild symptoms versus moderate/severe symptoms as reported on the PGI-S), 
and treatment regimens (always been on prophylaxis versus been on prophylaxis or on-demand 
therapy).  In multi-group CFA, assessment of invariance includes two distinct parts namely 
testing of measurement invariance (i.e., the latent construct is being measured in the same way 
by the indicators across groups of patients) and structural invariance (i.e., the groups of patients 
differ in their distribution and/or means of the latent construct).  The current study focused on 
assessing only the measurement invariance of the SF-12v2 across sub-groups of adults with 
hemophilia.  The testing of measurement invariance of the SF-12v2 was carried out using a 
series of tests and nested-model comparisons that imposed successive restrictions on model 
parameters.  Chi-square tests examining statistically significant improvement in model fit 
between nested models were carried out using the DIFFTEST option in Mplus 7.31 (Muthen & 
Muthen, Los Angeles, CA) in conjunction with weighted least squares (WLSMV) estimation for 
categorical (ordinal) indicators.  The WLSMV estimation technique with delta parameterization 
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was used considering that the items on the SF-12v2 are measured on an ordinal scale with a 
limited number of response options (B. Muthén, 1984).  
 The current study employed a “step-up” approach to the order in which restrictions on 
model parameters within multiple-groups CFA were evaluated.  In this strategy, invariance 
testing started with the least restricted solution and analysis proceeds with the evaluation of 
subsequent models with greater number of restrictive constraints (Brown, 2015).  Initially an 
omnibus test of equality of the overall indicator covariance matrices across patient sub-groups 
was conducted.  This involved testing the CFA separately in each group.  On the whole, if the 
covariance matrices did not differ between groups then it was considered that the assumption of 
measurement invariance is met and testing was conducted.  The first step involved the test of 
equal factor structures (i.e., whether the number of latent constructs and pattern of indicator 
loadings on latent dimensions are identical across groups).  This is known as the test of equal 
form or configural invariance (Brown, 2015).  The second step entailed placing an additional 
constraint of equal factor loading on the model from step 1.  This test is often referred to as the 
test of metric invariance or weak factorial invariance (Brown, 2015).  The final step included the 
restrictions from step 2 (i.e., equal factor loadings) plus the additional constraint of equal 
indicator intercepts (or thresholds) across patient sub-groups.  This test has been alternatively 
termed as scalar invariance or strong factorial invariance (Brown, 2015).  Mplus shortcuts for 
configural, metric, and scalar invariance were also used to ensure that similar results were 
obtained using both approaches.  Further specification of these models can be found in the Mplus 
user’s guide (Muthén & Muthén, 2015).  
 The χ2 statistic for the WLSMV estimator cannot be used for chi-square difference testing 
in the regular way in Mplus. Therefore the DIFFTEST option in Mplus was used during 
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invariance testing to evaluate model fit across patient sub-groups (Muthén & Muthén, 2015).  If 
the fit, after adding each restrictive constraint to the model, was found to be significantly worse 
than the previous less constrained model, then further invariance testing was stopped and an 
inspection of the modification indices was carried out.  Starting from the largest modification 
index, problematic constraints were removed at each level of invariance testing until the model 
fit was found not to be worse as compared to the previous model with fewer constraints on 
model parameters.  Thus in cases where full invariance did not hold, an examination of partial 
measurement invariance was carried out.  Further testing by placing more restrictive parameter 
constraints was only continued if atleast one indicator (besides the marker indicator) was found 
to be invariant across patient sub-groups (Brown, 2015). 
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RESULTS 
Sample Description 
The study sample included a total of 218 adults with hemophilia (Table 3.1).  169 
(77.5%) of these patients were recruited using an online panel of hemophilia patients (i.e., Rare 
Patient Voice), 44 (20.2%) were recruited using a Facebook community of hemophilia patients 
(i.e., Hemo Friends), and 6 (2.3%) were recruited at the UMMC HTC.  The study sample largely 
included Caucasian (68.5%), males (79.5%) with hemophilia A (77.5%).  The mean age of adults 
with hemophilia who were enrolled into the study was 35.45(±12.3) years.  Based on the severity 
of hemophilia-related symptoms in the past 4 week, the study sample included four patient 
groups namely – no symptoms (14.2%), mild symptoms (30.6%), moderate symptoms (27.9%), 
and severe symptoms (39%).  Based on the treatment regimen, the study sample could be divided 
into three groups namely – always received clotting factor prophylactically (55.3%), received 
clotting factor both prophylactically and as episodic therapy (14.2%), and always received 
clotting factor episodically (20.5%).   
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Table 0.2: Demographic and clinical characteristics the study sample (N = 218) 
Characteristics N (%) 
Diagnosis   
   Hemophilia A 169 (77.5) 
   Hemophilia B 49 (22.5) 
Gender   
  Male 174 (79.5) 
  Female 24 (11.0) 
Age, mean (sd) 35.45 (±12.3) 
Race/Ethnicity   
  White/Caucasian 150 (68.5) 
  Other* 47 (21.5) 
Marital Status   
  Never Married 66 (30.1) 
  Married 98 (44.7) 
  Other† 34 (20.1) 
Education level   
  Less than high school 9 (4.1) 
  High school or technical school 30 (13.7) 
  College degree 128 (58.4) 
  Masters degree 17 (7.8) 
  Doctoral degree 6 (2.7) 
  Professional degree 8 (3.7) 
Employment Status   
  Employed/self–employed full time  103 (47.0) 
  Employed part–time 23 (10.5) 
  On disability 16 (7.3) 
  Other‡ 56 (25.6) 
Region of the country   
  Northeast 46 (21.0) 
  Midwest 40 (18.3) 
  South 54 (24.7) 
  West 58 (26.5) 
Health Insurance   
  Public 61 (27.9) 
  Private 113 (51.6) 
  Both  6 (2.7) 
  None 18 (8.2) 
Disease severity   
  Mild (5%-40% clotting factor activity) 42 (19.2) 
  Moderate (1%-5% clotting factor activity) 25 (11.4) 
  Severe (>1% clotting factor activity) 127 (58.0) 
  Not sure 3 (1.4) 
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Symptom Severity   
  No symptoms 31 (14.2) 
  Mild symptoms 67 (30.6) 
  Moderate symptoms 61 (27.9) 
  Severe symptoms 39 (17.8) 
Treatment Regimen   
  Always received on prophylaxis therapy 121 (55.3) 
  Received both prophylaxis and on-demand therapy  31 (14.2) 
  Always received on on-demand therapy 45 (20.5) 
Number of bleeding episodes in the past year, mean (sd) 11.69 (±19.1) 
Hemophilia-related surgery    
  Yes 73 (33.3) 
  No 124 (56.6) 
Number of hemophilia-related surgeries in the past year, 
mean (sd) 3.64 (±3.9) 
Comorbidities   
  Hepatitis C 80 (36.5) 
  HIVˠ 26 (11.9) 
  Depression 84 (38.4) 
  Inhibitors to clotting factor 41 (18.7) 
Annual number of hemophilia-related visits, mean (sd)   
  Hemophilia Treatment Center (HTC) 2.23 (±3.1) 
  Hematologist outside a HTC 0.83 (±1.8) 
  Primary Care Practitioner 2.42 (±4.2) 
SD standard deviation 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, 
Native Hawaiian/Other Pacific Islander, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with 
partner 
‡Other includes retired, home–maker, student, seeking work, etc. 
ˠHIV - Human Immuno Deficiency Virus. 
Patient recruitment – 169 (77.5%) from Rare Patient Voice, 44 (20.2%) from 
Hemo Friends, and 6 (2.3%) from UMMC HTC. 
  
Step 1: Establishing a measurement model for the SF-12v2 
Details related to establishing the best fitting two factor model for the SF-12v2 can be 
found in chapter 2 of this dissertation.  The final measurement model used for the measurement 
invariance analysis can be found in Figure 3.1 below. 
Step 2: Testing measurement invariance with respect to exogenous variables  
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Three separate multi-group CFA models were used in order to test for measurement 
invariance of the SF-12v2 across the three exogenous variables of interest (i.e., age, symptom 
severity, and treatment regimen). 
Age.  Based on a median split at 34 years of age, the study sample was divided into two age 
groups (i.e., adults with hemophilia between 18 to 34 years of age [n = 106] and adults with 
hemophilia greater than 34 years of age [n=91]).  Only 197 out of 218 patients with hemophilia 
responded to the age question on the survey.  The results for the measurement invariance 
analysis can be found in Table 3.2 below.
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Figure 0.1: Two Factor Model for the SF-12v2 based on Maurischat et al. (2008) 
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Table 0.3: Test of measurement invariance of the SF-12v2 in adults with hemophilia with respect to age (less than/equal to versus 
greater than 34 years of age) 
  χ2 df 
χ2 
diff 
df 
diff RMSEA (90% CI) WRMR CFI TLI 
Single-group solution          
Age less than or equal to 34 
years (n = 106) 129.07* 48   0.126 (0.100-0.153) 0.847 0.962 0.948 
Age greater than 34 years (n = 
91) 184.55* 48   0.125 (0.106-0.144) 1.061 0.964 0.950 
           
Measurement Invariance          
Equal Form (configural 
invariance) 230.15* 96   0.119 (0.099-0.139) 1.132 0.967 0.954 
Equal Factor Loadings (Metric 
invariance) 223.18* 106 7.176 10 0.106 (0.086-0.125) 1.158 0.971 0.964 
Equal indicator intercepts 
(Scalar invariance) 245.69* 136 40.01 30 0.090 (0.072-0.108) 1.281 0.973 0.974 
Note: df, degrees of freedom; χ2 diff, nested χ2 difference; RMSEA, Root Mean Square Error of Approximation; CI, 
Confidence Interval; WRMR, Weighted Root Mean Square Residual; CFI, Comparative Fit Index; TLI, Tucker-Lewis 
Index.                                                                                                                                                                                     
The chi-square (χ2) value for WLSMV estimator cannot be used for chi-square difference testing in the regular way.  
WLSMV difference testing is done using the DIFFTEST (χ2 diff) option in Mplus. 
*p-value <0.0001 
 
 
 
 
 90 
 
Initially an omnibus test of equality of the overall indicator covariance matrices was conducted 
in both the population subgroups (i.e., 18-34 years of age, greater than 34 years of age).  The 
model fit indices were comparable across both age groups.  Following the omnibus test, the three 
invariance tests of equal form, equal factor loadings, and equal indicator intercepts were carried 
out.  All three tests (configural, metric, and scalar invariance) indicated invariance across the two 
age groups as measured by insignificant differences in χ2 diff values.  The results for the test of 
equal form (configural invariance) suggest that the number of latent constructs and the pattern of 
indicator loadings on the LPF and LMF are identical across the two age groups.  The test of 
equal factor loadings (metric invariance) suggested that the indicators evidence equivalent 
relationships to the two latent constructs of LPF and LMF across both age groups (     χ2= 7.176, 
df = 10, p = 0.7087).  Finally, on the basis of the results of the equal factor loadings and equal 
indicator intercepts (     χ2= 40.01, df = 30, p = 0.1046) analysis, it was concluded that for any 
given value of LPF or LMF, the observed values of the SF-12 items are statistically equivalent 
across the two patient age groups and any observed differences in HRQOL between patient age 
groups were “true differences” and not systematic measurement artifacts. 
Symptom severity.  Adults with hemophilia were divided into two groups based on their 
symptom severity as assessed using the PGI-S.  One group included those with no/mild 
symptoms over the past 4 weeks (n = 98) while the other group included those with 
moderate/severe symptoms (n = 100).  A total of 197 patients with hemophilia responded to the 
self-reported symptom severity measure.  Symptom severity was dichotomized given the higher 
sample requirement for assessing measurement invariance across three or more groups.  The 
results for the tests of measurement invariance can be found in Table 3.3 below.
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Table 0.4: Test of measurement invariance of the SF-12v2 in adults with hemophilia with respect to symptom severity  (no/mild 
symptoms versus moderate/severe symptoms) 
  χ2 df χ2 diff 
df 
diff RMSEA (90% CI) WRMR CFI TLI 
Single-group solution          
No/Mild symptoms (n = 98) 166.86* 48   0.159 (0.133-0.186) 0.984 0.941 0.919 
Moderate/Severe symptoms (n = 
100) 99.78* 48   0.104 (0.075-0.133) 0.754 0.966 0.954 
           
Measurement Invariance          
Equal Form (configural 
invariance) 265.11* 96   0.133 (0.114-0.153) 1.24 0.953 0.935 
Equal Factor Loadings (Metric 
invariance) 264.22* 106 17.24 10 0.123 (0.104-0.141) 1.306 0.956 0.945 
Equal indicator intercepts 
(Scalar invariance) 284.69* 136 50.53ˠ 30 0.105 (0.088-0.122) 1.469 0.959 0.96 
Note: df, degrees of freedom; χ2 diff, nested χ2 difference; RMSEA, Root Mean Square Error of Approximation; CI, 
Confidence Interval; WRMR, Weighted Root Mean Square Residual; CFI, Comparative Fit Index; TLI, Tucker-Lewis 
Index.                                       The chi-square value for WLSMV estimator cannot be used for chi-square difference 
testing in the regular way.  WLSMV difference testing is done using the DIFFTEST option in Mplus. 
*p-value <0.0001; ˠp-value = 0.0109 
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The overall omnibus test of equality of the indicator covariance matrices across the groups 
suggested adequate and comparable fit across the two symptom severity groups.  The test for 
equal form (configural invariance) and equal factor loadings (metric invariance) suggested 
invariance across the symptom severity groups (     χ2= 17.24, df = 10, p = 0.0691).  However, 
the test for equal indicator intercepts (scalar invariance) indicated non-invariance across the 
symptom severity groups as indicated by a significant χ2 diff value (    χ2= 50.53, df = 30, p = 
0.0109).  After an examination of the modification indices, we proceeded with partial invariance 
testing by relaxing the constraint on the indicator threshold for item 9 across both the symptom 
severity groups.  Relaxing this constraint not only improved the model fit (RMSEA [90% CI] = 
0.103 [0.086 – 0.120]; CFI = 0.960; TLI = 0.961; WRMR = 1.436) but also resulted in an 
invariant model as indicated by the non-significant difference in the χ2 value (p = 0.051) as 
compared to the metric model which held only factor loadings to equality across both groups. 
Treatment regimen.  Adults with hemophilia included in the study sample were divided into two 
groups based on their treatment regimen – patients who had always been on prophylaxis therapy 
(n = 121) and those who had not always been on prophylaxis therapy (i.e., hemophilia patients 
who were on both prophylaxis and on-demand therapy, or who had always been on on-demand 
therapy [n =76]).  A total of 197 patients with hemophilia responded to the self-reported 
treatment regimen item.  Treatment regimen was dichotomized into the following two groups 
based on previous literature (Royal et al., 2002).  The results for the tests of measurement 
invariance based on the treatment regimen can be found in table 3.4 below.
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Table 0.5: Test of measurement invariance of the SF-12v2 in adults with hemophilia with respect to treatment regimen (Always on 
prophylaxis versus prophylaxis or on-demand treatment) 
  χ2 df χ2 diff 
df 
diff RMSEA (90% CI) WRMR CFI TLI 
Single-group solution          
Always Prophylaxis (n = 
121) 145.06* 48   0.129 (0.105-0.154) 0.901 0.958 0.942 
Prophylaxis/On-demand (n 
= 76) 98.07* 48   0.117 (0.084-0.150) 0.716 0.971 0.960 
           
Measurement Invariance          
Equal Form (configural 
invariance) 242.41* 96   0.124 (0.105-0.144) 1.151 0.964 0.950 
Equal Factor Loadings 
(Metric invariance) 242.34* 106 13.68 10 0.114 (0.095-0.133) 1.200 0.966 0.958 
Equal indicator intercepts 
(Scalar invariance) 307.59* 136 81.94* 30 0.113 (0.096-0.130) 1.446 0.957 0.959 
Note: df, degrees of freedom; χ2 diff, nested χ2 difference; RMSEA, Root Mean Square Error of Approximation; CI, 
Confidence Interval; WRMR, Weighted Root Mean Square Residual; CFI, Comparative Fit Index; TLI, Tucker-Lewis 
Index.                                       The chi-square value for WLSMV estimator cannot be used for chi-square difference 
testing in the regular way.  WLSMV difference testing is done using the DIFFTEST option in Mplus. 
*p-value <0.0001 
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Based on the results of the omnibus test of the equality of indicator covariance matrices, it was 
concluded that the two factor model of the SF-12v2 had a comparable fit across both the 
treatment groups.  The tests for equal form (configural invariance) and equal factor loadings 
(metric invariance) suggested invariance across both treatment groups (    χ2= 13.68, df = 30, p = 
0.187).  However, upon adding the constraint of equality of indicator intercepts to the metric 
model, the assumption of scalar invariance did not hold (   χ2= 81.94, df = 30, p < 0.0001).  
Measurement invariance at the scalar level could not be achieved even after an examination of 
modification indices.  In conclusion, the finding of invariance at the configural and metric level 
assures that comparisons across hemophilia treatment regimens can be made as to relationships 
between factors (i.e., factor loadings).  However, considering the finding of non-invariance at the 
scalar level indicates that caution must be exercised in analyses involving comparisons of item 
means between groups. 
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DISCUSSION 
The SF-12v2 is one of the most widely used generic HRQOL instrument.  Several studies 
have established the psychometric properties of the SF-12v2 in the US general population and 
among patients across several disease states (Fleishman & Lawrence, 2003; Maurischat et al., 
2008; McBride et al., 2009; Okonkwo et al., 2010).  Before conducting comparisons of patient 
subgroups in terms of their HRQOL, it must be ensured that patients at the same level of the 
underlying latent HRQOL construct assign the same meaning to the questionnaire items and that 
patient responses on these items are not influenced by their demographic and/or clinical 
characteristics such as age, gender, symptom severity, or treatment regimen.  If such patient 
characteristics do not impact the psychometric properties of the observed questionnaire items 
then the assumption of measurement invariance is said to be met.  The current study assessed 
whether the measurement properties of the SF-12v2 are invariant with respect to age, symptom 
severity, and treatment regimen among adults with hemophilia in the US.   
The two factor model of the SF-12v2 as per the approach adopted by Maurischat and 
colleagues was used as the measurement model for the current study.  The factorial validity of 
this measurement model of the SF-12v2 among adults with hemophilia has been previously 
established in chapter 2 of this dissertation.  The results of the current study suggested that the 
SF-12v2 was invariant across age groups.  Differential item functioning (DIF) was seen with 
respect to item 9 “calm and peaceful” among adults with hemophilia across symptom severity 
levels.  Comparison of the SF-12v2 across hemophilia treatment regimens supported the 
 96 
 
presence of “approximate invariance” (Millsap, 2005) such that although non-invariance across 
treatment groups was seen at the scalar level (i.e., equal indicator intercepts), the association 
between the SF-12 items and the underlying latent factors was largely equivalent across 
treatment groups in terms of pattern and coefficients of factor loadings. 
  The results of the current study suggested that the assumption of measurement invariance 
with respect to age was satisfied at the configural, metric, and scalar level in the total study 
sample.  This suggests that if younger and older adults with hemophilia had the same underlying 
HRQOL, they would respond similarly to the items on the SF-12v2.  Thus any differences seen 
in HRQOL across age groups among adults diagnosed with hemophilia can be interpreted as true 
differences and not artifacts of systematic measurement error.  Previous studies have reported the 
detrimental effects of increasing age on the HRQOL of patients with hemophilia.  Miners and 
colleagues reported that besides age, none of the clinical variables, were found to be significant 
predictors of HRQOL among patients with severe hemophilia A and B (Miners et al., 1999).   
Several other studies have reported similar findings (Solovieva, 2001; Trippoli et al., 2001; 
Wang, Zhang, Li, Zhao, & Yang, 2004).  Therefore the finding that HRQOL as measured by the 
SF-12v2 has the same meaning across age groups holds key importance in allowing future 
researchers to conduct planned HRQOL comparisons across different age groups of hemophilia 
patients. 
 The results from the multi-group CFA across symptom severity levels among adults with 
hemophilia revealed the presence of measurement invariance at the configural and metric level.  
Non-invariance was found at the scalar invariance level specifically with respect to item 9 “calm 
and peaceful”.  Previous studies which have assessed measurement invariance of the SF-12 
among other populations have found a similar differential item functioning (DIF) effect with 
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respect to item 9 on the scale.  A study examining the measurement invariance of the SF-12v2 
among Latina, European-American, and African-American postpartum women in the US 
reported a DIF effect for item 9 indicating that Latinas were more likely to report feeling calm 
and peaceful within 2 weeks after their baby was born as compared to European-Americans 
(Desouky, Mora, & Howell, 2013).  In a study assessing the presence of DIF among items on the 
SF-12v1 in the general US population, Fleishman and Lawrence reported that Latinos were more 
likely to endorse item 9 as compared to their European-American counterparts (Fleishman & 
Lawrence, 2003).  Perkins and colleagues found the presence of age and education-related DIF 
for this item while assessing the measurement invariance of the SF-36v1 in a national sample of 
healthy adults in the US (Perkins, Stump, Monahan, & McHorney, 2006).  The authors indicated 
that older and less educated individuals were more likely to endorse item 9 “calm and peaceful” 
as compared to their younger and more educated counterparts.  Therefore, based on prior 
evidence and the results of the current study, a revision of item 9 may improve the equivalence 
of the SF-12v2 in future research.  Overall our findings suggest that the items on the SF-12v2 are 
interpreted equivalently across adults with hemophilia having varying symptom severity levels.  
Such a finding has key implications in establishing the known-groups validity of the instrument 
in this patient population and allowing comparisons of the HRQOL across different severity 
levels of patients with hemophilia. 
 The results for the test of measurement invariance across treatment regimens among 
adults with hemophilia suggested the presence of invariance at the configural and metric level.  
In general, configural and metric invariance is sufficient for establishing psychometric 
equivalence of the SF-12v2 (Morales, Diamant, & Hays, 2016).  This attests that the LPF and the 
LMF are related to the items on the SF-12v2 in the same way for adults with hemophilia who 
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have always been on prophylaxis and for those who have not always been on prophylaxis 
therapy.  Further constraints equating the intercepts (scalar invariance) across the two groups 
resulted in a chi-square difference value which was significant at α = 0.05, thereby indicating 
non-invariance at the scalar level.  This may be because of unequal sample sizes between the two 
treatment groups.  Also, invariance analyses based on large sample sizes very often result in a 
significant chi-square difference value and increased risk of rejection of good models (Clench-
Aas, Nes, Dalgard, & Aarø, 2011).  In the current study, an examination of other fit indices 
besides the χ2 difference value for the scalar model indicated that these were either improved 
(RMSEA or TLI) or slightly decreased (CFI and WRMR) as compared to the metric model.  
Based on the suggestion of “approximate invariance”, although the scalar model would be 
rejected by a statistical test of exact fit (i.e., chi-square difference value), it was retained upon an 
assessment of other fit indices (Millsap, 2005).  The implication of this practice is that some 
degree of violation of the assumption of measurement invariance is tolerated; resulting in 
“approximate invariance” rather than exact invariance as defined in theory.  In the context of the 
current study, approximate invariance for the scalar model implies that group means on the latent 
variables are comparable across treatment groups among adults with hemophilia.   
 Limitations of the current study include the fact that all data on demographic and clinical 
variables of interest were self-reported and not verified by a review of medical records.  Another 
limitation relates to sample sizes for each group.  In some cases the groups being compared had 
unequal sample sizes.  For example, the number of patients who had always been on prophylaxis 
were almost one and half times those who had not been on prophylaxis therapy throughout.  
Third, the current study employed a cross sectional design and therefore it was not possible to 
assess longitudinal measurement invariance of the SF-12v2 among adults with hemophilia.  
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Future research should focus on determining whether hemophilia patients interpret items on the 
SF-12v2 equivalently over a longer period of time.  Finally, model fit indices have largely been 
developed in the context of parametric maximum likelihood estimation.  The application of these 
model fit statistics to non-parametric ordinal models should be made cautiously.   
 The results of our study have demonstrated that the SF-12v2 can provide accurate 
estimates of HRQOL among adults with hemophilia in the US.  Assessing and ascertaining 
invariance is essential for improving measurement.  The current study indicated that the SF-12v2 
was invariant with respect to age of the study participants.  The presence of DIF was seen with 
respect to item 9 “calm and peaceful” while comparing hemophilia patients across different 
severity levels.  This item has shown DIF effects among other patient populations as well as in 
the general US population and could possibly be considered for revision.  Finally, findings for 
the invariance analysis across hemophilia treatment regimens lend support to the interpretation of 
“approximate invariance”.  Although HRQOL comparisons across hemophilia patients on 
different treatment regimens can be carried out, these results must be interpreted with caution.  
Overall, the SF-12v2 was largely invariant with respect to age, symptom severity, and treatment 
regimen among a sample of US adults with hemophilia.   
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INTRODUCTION 
According to the International Society for Quality of Life Research (ISOQOL), health-related 
quality of life (HRQOL) is “the functional effect of a medical condition and/or its consequent 
therapy upon a patient” (International Society for Quality of Life Research, 2015).  Hemophilia 
is a rare genetic blood coagulation disorder affecting men. It is caused by a deficiency of clotting 
factor VIII or IX.  Patients with hemophilia experience bleeding into joints or muscles which 
may result in chronic pain and reduce the range of joint motion (Dolan et al., 2009).  Depression, 
anxiety, and psychological distress among hemophilia patients lead to a deterioration in their 
mental well-being (Ghanizadeh & Baligh-Jahromi, 2009).  Individuals with hemophilia must be 
careful about participating in activities such as contact sports because immediate bleeding may 
ensue.  This may impact their social participation and peer integration (Aznar, Magallón, Querol, 
Gorina, & Tusell, 2009; Mackensen, 2007).  Thus the physical, mental and social consequences 
of the disease serve to reduce the health-related quality of life (HRQOL) of patients.  HRQOL is 
increasingly being considered as an important outcome among hemophilia patients.  
Purpose of the study 
Several studies have assessed the HRQOL of patients with hemophilia.  Majority of these 
studies have reported that hemophilia patients suffer from worse physical HRQOL as compared 
to the healthy population.  The mental HRQOL of patients with hemophilia was found to be 
similar to the general population (Aznar et al., 2009; Lindvall, Von Mackensen, & Berntorp, 
2012; Molho et al., 2000; Poon, Doctor, & Nichol, 2014).  Previous studies which have 
 107 
 
evaluated predictors of HRQOL among hemophilia patients have examined the role of clinical 
(i.e., disease severity, comorbid conditions such as hepatitis C or human immunodeficiency virus 
[HIV] infection) and socio-demographic determinants (Miners et al., 1999; Royal et al., 2002; 
Szucs, Öffner, and Schramm, 1996).  However, these studies have generally overlooked the role 
of psychosocial variables such as social support, coping strategies, and patient self-efficacy 
which have been identified as essential predictors of HRQOL among other disease states 
including HIV and osteoarthritis (Luszczynska, Sarkar, & Knoll, 2007a; McKnight, Afram, 
Kashdan, Kasle, & Zautra, 2010).  Knowledge about these psychosocial factors not only assist 
healthcare providers and caregivers in improving care provided to individuals with hemophilia, 
but also potentially enable patients to better understand and self-manage their disease condition.  
Such evaluations can assist both clinicians and healthcare policymakers in designing programs 
aimed at increasing the level of social support provided, fostering the use of adaptive coping 
strategies, and overall ensuring better health among these patients.  Therefore the current study 
assessed psychosocial factors which affect the HRQOL of individuals with hemophilia using a 
theory-driven approach. 
Conceptual framework 
Employing a theory-based assessment is essential to arrive at a holistic understanding of 
the impact of hemophilia on patient well-being.  It has been suggested that stress and coping are 
concepts which can be influenced by clinicians and therefore theoretical models based on stress 
and coping theories are particularly well suited for HRQOL research in rare genetic disorders 
(Biesecker & Erby, 2008).  The Lazarus and Folkman’s (1984) cognitive-behavioral model is 
based on a theory of stress, appraisal, coping, and adaptation.  According to this theory, 
individuals respond to stressors, such as living with hemophilia, by making cognitive and 
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emotional appraisals of the stressor.  An individual’s appraisal of these stressors depends upon 
the personal significance of the stressor, its cause, severity, one’s susceptibility to the stressor as 
well as the ability to cope with the problems and the emotions associated with the stressor 
(Lazarus & Folkman, 1984).  These appraisals govern coping behaviors because the likelihood 
that one can change or adapt to a stressor will direct one’s ability to cope with it and also 
determine the coping mechanism which will be adopted (Bombardier, D’Amico, & Jordan, 
1990).  The adopted coping strategies in turn gradually help attain or restore optimal HRQOL.  
Therefore an individual’s ability to adapt to a stressor is governed by cognitive appraisal of the 
stressful event and the associated coping response.  This model can therefore be adapted to 
identify psychosocial predictors of HRQOL among patients with rare diseases such as 
hemophilia.  This framework has been modified and previously used by studies to identify 
determinants of HRQOL among patients with breast cancer, colon cancer, and diverse chronic 
conditions (Bombardier et al., 1990; Miller, Gordon, Daniele, & Diller, 1992; Northouse et al., 
2002; Northouse, Templin, & Mood, 2001). 
 For the purposes of the current study, an adapted version of the Lazarus and Folkman’s 
cognitive-behavioral model of stress and coping was employed to identify antecedents and 
cognitive pathways that influence adaptation responses (i.e., restoring optimal HRQOL) to a 
chronic disease such as hemophilia (Figure 1).  HRQOL has been previously considered as an 
outcome of the adaptation process among patients with breast cancer, HIV, and osteoarthritis 
(Luszczynska, Sarkar, & Knoll, 2007; McKnight, Afram, Kashdan, Kasle, & Zautra, 2010; 
Northouse et al., 2002).  Specifically, it is hypothesized that the influence of hemophilia-related 
disability on HRQOL will be partially mediated by the social support received by the patient and 
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the adopted coping strategy.  Further it is also hypothesized that the impact of coping and social 
support on HRQOL will depend on the level of patient self-efficacy. 
Model Constructs 
Disability 
Patients with hemophilia experience progressive joint impairments because of repeated 
bleeding episodes. This can lead to serious functional disabilities (van Genderen et al., 2006). 
These functional disabilities can significantly impact their HRQOL. Barr et al. (2002) measured 
health utilities among hemophilia patients and reported major impairments in the domains of 
mobility, ambulation, and pain (Barr et al., 2002).  In another study, functional limitation due to 
existing joint damage was the major predictor of lower physical HRQOL among adult Canadian 
hemophilia patients (Walsh et al., 2008). A Dutch study showed that disability, as measured by 
impairments in activities of daily living (ADL) and joint impairment, significantly influenced 
well-being of hemophilia patients (Triemstra et al., 1998).  In previous research, the relationship 
between disability and HRQOL has been found to be mediated by perceived social support and 
the adopted coping style (Newsom & Schulz, 1996; Santavirta et al., 2010). 
Perceived Social Support 
According to Stewart (1993), social support is defined as “interactions, with family 
members, friends, health professionals and peers, that communicate information, reliable 
alliance, aid and esteem” (Stewart, Streiner, & Norman, 1995).  A German study suggested that 
social support and life satisfaction explained the highest proportion of variance in HRQOL 
among adolescents with hemophilia (Bullinger & von Mackensen, 2008).  Iannone and 
colleagues reported that the perceived lack of social support was significantly and positively 
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associated with higher depression scores among adults with hemophilia in the US (Iannone et al., 
2015).  Klein et al. (1994) examined the impact of social support and coping on stress resiliency 
among adult hemophiliacs with HIV. Social support (i.e. marital satisfaction and peer support) 
was found to be a significant predictor of patients’ functioning and psychological well-being 
(Klein, Forehand, Armistead, & Wierson, 1994).   
Coping 
Lazarus and Folkman (1984) define coping as “cognitive and behavioral efforts to 
master, reduce, or tolerate the internal and/or external demands that are created by the stressful 
situation”.  There are two types of coping mechanisms. Problem-focused/task-oriented coping 
(TOC) aims at the management of the external environment associated with the stressor by 
seeking information about what to do or holding back from making premature decisions.  This is 
also known as adaptive coping.  Emotion-oriented coping (EOC) is concerned with the 
regulation of the internal affective emotions which are a consequence of the stressor (Lazarus & 
Folkman, 1984). EOC strategies do not change a damaging situation but they make a person feel 
better. Avoidance coping (AC) is a maladaptive coping strategy where an individual completely 
avoids or is in denial of the illness. This is considered as a sub-strategy of EOC (Fledderus, 
Bohlmeijer, & Pieterse, 2010) and has been linked to diminished QOL (Cassis et al., 2012). EOC 
and AC strategies are considered to be maladaptive coping strategies.  Binnema et al. (2014) 
studied coping strategies among adults with severe hemophilia in the Netherlands.  Patients with 
hemophilia were found to use adaptive coping strategies as often as healthy controls.  However 
they used significantly less maladaptive coping as compared to the control group.  Use of 
maladaptive coping was found to be positively and significantly correlated with poor socio-
psychological health, lower participation in daily activities and lesser social interactions among 
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severe hemophilia patients (Binnema, Schrijvers, Bos, Schuurmans, & Fischer, 2014).  Klein and 
colleagues (1994) demonstrated that maladaptive was associated with poorer functioning among 
hemophilia patients and HIV (Klein et al., 1994).  There is evidence that coping mediates the 
disability and psychosocial well-being relationship among adults with hemophilia (Santavirta et 
al., 2010). 
Perceived Self-Efficacy 
Self-efficacy is the amount of confidence that patients have in managing the demands 
associated with their chronic illness (Bandura, 1994).  Among individuals with hemophilia self-
management skills are essential for achieving higher treatment adherence, slowing disease 
progression and restoring optimal HRQOL (Teitel et al., 2004).  Lock et al. (2014) assessed the 
reliability and validity of the hemophilia-specific self-efficacy scale (HSES) among children who 
were on prophylactic home treatment in the US (Lock et al., 2014).  It was found that higher self-
efficacy scores were significantly correlated with higher patient HRQOL.  Self-efficacy has been 
previously shown to have a moderating impact on the coping and HRQOL relationship.  At 
higher levels of self-efficacy, the negative impact of maladaptive coping strategies on HRQOL 
was found to be diminished among patients with acquired brain injury (Brands, Köhler, Stapert, 
Wade, & van Heugten, 2014).  A similar relationship was tested among patients with rheumatoid 
arthritis where self-efficacy was found to moderate the relationship between coping and 
emotional outcomes (i.e., anxiety and depression) (Lowe et al., 2008).  Previous studies have 
also suggested that people with lower self-efficacy were likely to be less physically active in 
spite of having high perceived social support (Dishman et al., 2009; Warner, Ziegelmann, Schuz, 
Wurm, & Schwarzer, 2011).  In the context of the theoretical framework employed by the 
current study, self-efficacy was treated as a form of appraisal.  It was hypothesized that at higher 
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levels of self-efficacy, the impact of coping strategies and social support on HRQOL will be 
enhanced among adults with hemophilia.  Certain studies in the literature have also found self-
efficacy to play the role of a mediator in the disability-HRQOL relationship (Abbott, Tyni-Lenn, 
& Hedlund, 2010).  Therefore in addition to the above hypothesis, we also tested the role of self-
efficacy as a mediator. 
Research hypotheses 
Several hypotheses were tested in this study.  First, it was hypothesized that higher levels 
of disability among adults with hemophilia will be associated with lower HRQOL.  Second, it 
was hypothesized that adults with hemophilia with higher levels of perceived social support will 
have a higher HRQOL.  Third, the use of adaptive coping strategies will be associated with better 
HRQOL among adults with hemophilia.  Fourth, the impact of disability on HRQOL will be 
partially mediated by the perceived social support and the coping strategies adopted by adults 
with hemophilia.  Fifth, at higher levels of self-efficacy, the impact of maladaptive coping 
strategies on HRQOL will be diminished.  Sixth, at higher levels of self-efficacy, the impact of 
adaptive coping strategies on HRQOL will be enhanced among adults with hemophilia.  Last, at 
higher levels of self-efficacy, the impact of perceived social support on HRQOL will be 
enhanced among adults with hemophilia.         
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METHODS 
Study Design 
 A prospective, cross-sectional design was employed by the current study.  An Internet-
based survey designed using Qualtrics (Qualtrics Inc., Provo, UT) was self-administered to 
adults with hemophilia.  The study received approval under the exempt status from the 
University of Mississippi Institutional Review Board. 
Study Sample 
  The study population for the current study included adult patients (≥ 18 years) with 
hemophilia A or B.  Female patients as well as patients with other blood coagulation disorders 
were excluded from the study sample.  The internet-based survey for the current study was 
administered to adults with hemophilia enrolled with a patient panel called Rare Patient Voice as 
well as through a private Facebook community of hemophilia patients called Hemo Friends.  
Considering hemophilia is a rare disease, patients were also recruited with the assistance from 
the University of Mississippi Medical Center Hemophilia Treatment Center in Jackson, MS. 
Study procedures 
 An email explaining the nature and purpose of the study was sent out to all potential 
respondents.  Participants were assured about the anonymity and confidentiality of their 
responses.  It was also emphasized that participation in the study was voluntary.  The email also 
contained a URL link to the study survey.  The survey was active for 3 months from October 31, 
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2015 to February 1, 2016.  $10 Amazon gift cards were provided to all respondents as a token of 
appreciation. 
Sample Size 
 The sample size requirements for the current study were based on the analysis technique 
used to address the study objectives.  The current study used structural equation modeling (SEM) 
in order to assess the direct and indirect relationships among the study variables and identify 
predictors of HRQOL among adults with hemophilia.  Kline (2005) recommends that a sample 
size of greater than 200 is considered to be acceptable for SEM.  Based on this recommendation, 
a minimum sample size of 200 adults with hemophilia was needed for this study. 
Study Measures 
SF-12 Health Survey Version 2 (SF-12v2).  The SF-12v2 is a shorter version of the Short-Form 
36 Health Survey.  It provides information on eight subdomains of HRQOL namely general 
health (GH, one item), physical functioning (PF, two items), social functioning (SF, one item), 
role physical (RP, two items), bodily pain (BP, one item), vitality (VT, one item), role emotional 
(RE, two items), and mental health (MH, two items).  These subdomains can be further 
aggregated into the physical component summary (PCS) and the mental component summary 
(MCS) scores (Ware, Kosinski, & Keller, 1996).  The PCS and MCS scores are calculated using 
the Optum Scoring Software with higher scores indicating better HRQOL.  However, for the 
purposes of this study we extracted latent variables (i.e., Latent Physical Factor and Latent 
Mental Factor) instead of using PCS and MCS scores. 
Health Assessment Questionnaire - Disability Index (HAQ-DI).  The Stanford Arthritis Center 
Health Assessment Questionnaire (HAQ) was used to obtain a measure of the hemophilia-related 
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disability of the study participants (Bruce & Fries, 2005).  This scale has been previously used to 
assess disability among adults with hemophilia (Santavirta et al., 2010).  The HAQ disability-
index questionnaire includes 2 to 3 questions (20 items totally) about each of the 8 areas of 
activity of daily living (ADL) namely rising, dressing and toilet, eating, walking, hygiene, reach, 
grip, and miscellaneous activities.  Each item is scored on a 4-point scale labeled as 0 = “no 
difficulty,” 1 = “some difficulty,” 2 = “much difficulty or with assistance,” and 3 = “unable to 
perform.” The highest item score under each area of ADL determines the score for that area 
unless the respondent requires aid from another individual or an assistive device.  Activities that 
require assistance from another individual or the use of an assistive device receives a score of 2.  
The scores for each ADL area are summed and divided by 8 in order to obtain a functional 
disability index.  The HAQ-DI usually takes about 5 minutes to complete.    The HAQ-DI has 
been previously validated among patients with arthritis (Bruce & Fries, 2003). 
Multidimensional Scale of Perceived Social Support (MSPSS).  Patients’ perceived social 
support received from family, friends and significant others will be measured by using the 
MSPSS (Zimet, Dahlem, Zimet, & Farley, 1988).  The instrument consists of 12-items measured 
on a seven point linear numeric scale from 1 = ‘very strongly agree’ to 7 = ‘very strongly 
disagree’.  An overall social support score is calculated by taking the mean of the 12 items with 
higher scores indicating greater perceived social support by PWH.  This scale has been 
previously validated in patients with psychiatric/psychological problems (Eker & Arkar, 1995).   
Brief Coping Orientation to Problem Experiences (Brief COPE).  The coping style of adults 
with hemophilia will be assessed using the 28-item Brief COPE.  This instrument can broadly 
help assess the use of adaptive and maladaptive coping strategies.  The adaptive coping domain 
includes 16 items related to acceptance, active coping, humor, planning, positive reframing, use 
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of emotional support, and use of instrumental support. Maladaptive coping includes 12 items 
related to behavioral disengagement, denial, self-blame, self-distraction, substance abuse, and 
venting (Meyer, 2001).  Responses to items are assessed using a 4-point linear numeric scale 
with end points labeled as 1 = “I haven’t been doing this at all” to 4 = “I have been doing this a 
lot”.  Items related to substance abuse were not included considering the sensitivity of these 
items.  Scores for items within each coping domain are summed in order to obtain a total 
adaptive and maladaptive coping score with higher scores indicating greater use of a particular 
coping strategy. 
Generalized Self-Efficacy Scale (GSES).  The GSES is a 10-item measure which was used to 
assess self-efficacy among adults with hemophilia.  Responses on the GSES are assessed using 
on a 4-point linear numeric scale with endpoints ranging from 1 = “I totally disagree” to 4 = “I 
totally agree”.  Scores for the GSES items are summed to obtain a total self-efficacy score from 
10 to 40.  Higher scores indicate greater general self-efficacy (Jensen & Karoly, 1991, 1992).  
The concepts of general self-efficacy and hemophilia-specific self-efficacy were considered to be 
related although self-efficacy is considered to be a task-specific concept.  Such an approach to 
assessing self-efficacy is supported by literature in other disease states (Jensen, Turner, & 
Romano, 1992). 
Demographic and Health Information.  The following variables were used as covariates in all 
analyses: age, race/ethnicity (Caucasian, African American, Asian, Hispanic, American Indian, 
Native Hawaiian, other), education status (less than high school, high school, college degree, 
master’s degree, doctoral degree, professional degree, other), occupation status (employed full-
time, employed part-time, self-employed, retired, seeking work, student, other), marital status 
(single, married, divorced, separated, widowed, not married but living with a partner, other), type 
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of hemophilia (hemophilia A or B), disease severity (mild, moderate, severe), number of bleeds 
experienced in the last month, treatment regimen (prophylaxis, on-demand), hemophilia-related 
comorbidities (HIV, HCV infection).     
Statistical Analysis  
   Descriptive statistics were used to summarize the study variables.  Means and 
percentages were reported for the continuous variables. Frequencies and proportions were 
reported for summarizing the categorical variables.  Correlations were assessed between the 
study variables using Pearson’s correlation coefficient.  Differences in group proportions for 
categorical variables were calculated using chi-square (χ2) tests.  Internal consistency reliability 
was examined for all scales by calculating the Cronbach’s alpha (α).  An α-value ≥ 0.70 was 
considered to be an indication of adequate internal consistency reliability.  Summated scales 
were also created for the analyses. 
SEM was used to test the aforementioned theoretical relationships.  A robust weighted 
least squares (i.e., WLSMV) estimator was used to in order to account for the ordinal nature of 
the SF-12 items (Muthén, 1984).  The assumption of multivariate normality and linearity were 
tested by assessing the absolute skewness and kurtosis indices (Kline, 2005).  The proposed 
theoretical relationships were tested using a single model (Figure 4.1).  This model tested the 
mediating role of perceived social support and coping in the disability and HRQOL relationship.  
Additionally, the model tested the moderating impact of self-efficacy on the social support and 
HRQOL relationship as well as the coping and HRQOL relationship.  The moderated mediation 
approach suggested by Hayes (2013) was employed for conducting the analysis for the SEM 
model.  HRQOL as measured on the SF-12v2 was used as a latent variable and operationalized 
using the latent mental factor (LMF) and the latent physical factor (LPF).  The GH, PF, RP, and 
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BP sub-domain items were allowed to load onto a LPF.  The RE, MH, VT, and SF sub-domain 
items were allowed to load onto a LMF.  The residuals for each of the two PF, RP, RE, and MH 
items were allowed to be correlated.  The LPF and LMF were also correlated.  Disability, 
perceived social support, adaptive coping, maladaptive coping, and self-efficacy were treated as 
measured variables in the SEM models.  For testing the moderating effect of self-efficacy, 
interaction terms were created for social support, adaptive coping, and maladaptive coping with 
self-efficacy.   
Model fit for the model was assessed using the following five fit statistics.  The χ2 
statistic, the root mean square error of approximation (RMSEA), the Tucker Lewis Index (TLI), 
the comparative fit index (CFI), and the weighted root mean square residual (WRMR).  It has 
been suggested that for a well-fitting model, the RMSEA, TLI, CFI and WRMR must be ≤ 0.08, 
≥0.92, ≥0.93, and  ≥1.00 respectively (Bagozzi & Yi, 2012; Newsom, 2015).  Non-significant 
paths were eliminated and parameters were added to arrive at the best-fitting model based on the 
underlying theory in addition to the standardized residuals and modification indices. All analyses 
were carried out using Mplus version 7.31 (Muthen & Muthen, Los Angeles, CA).
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Figure 0.1: Hypothesized model for the study 
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RESULTS 
Descriptive statistics 
The study sample included 218 adults with hemophilia.  Responses from 21 adults with 
hemophilia were excluded due to ≥15% missing data on study measures mentioned in Figure 4.1.  
The mean age of the study sample was 35.45 (±12.3) years.  The majority of the patients 
included in the study were white (68.5%), males (79.5%) diagnosed with hemophilia A (77.6%).  
Most of the respondents had a college degree (58.4%), were employed/self-employed full time 
(47%), and had private health insurance (51.6%).  The study sample included an even 
distribution of adults with hemophilia from all four census regions of the country.  Details related 
to the demographic and clinical characteristics of patients with hemophilia enrolled in the study 
can be found in Table 4.1. 
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Table 0.1: Demographic and clinical characteristics the study sample (N = 219) 
Characteristics N (%) 
Diagnosis   
   Hemophilia A 170 (77.6) 
   Hemophilia B 49 (22.4) 
Gender   
  Male 174 (79.5) 
  Female 24 (11.0) 
Age, mean (sd) 35.45 (±12.3) 
Race/Ethnicity   
  White/Caucasian 150 (68.5) 
  Other* 47 (21.5) 
Marital Status   
  Never Married 66 (30.1) 
  Married 98 (44.7) 
  Other† 34 (20.1) 
Education level   
  Less than high school 9 (4.1) 
  High school or technical school 30 (13.7) 
  College degree 128 (58.4) 
  Masters degree 17 (7.8) 
  Doctoral degree 6 (2.7) 
  Professional degree 8 (3.7) 
Employment Status   
  Employed/self–employed full time  103 (47.0) 
  Employed part–time 23 (10.5) 
  On disability 16 (7.3) 
  Other‡ 56 (25.6) 
Region of the country   
  Northeast 46 (21.0) 
  Midwest 40 (18.3) 
  South 54 (24.7) 
  West 58 (26.5) 
Health Insurance   
  Public 61 (27.9) 
  Private 113 (51.6) 
  Both  6 (2.7) 
  None 18 (8.2) 
Disease severity   
  Mild (5%-40% clotting factor activity) 42 (19.2) 
  Moderate (1%-5% clotting factor activity) 25 (11.4) 
  Severe (>1% clotting factor activity) 127 (58.0) 
  Not sure 3 (1.4) 
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Symptom Severity   
  No symptoms 31 (14.2) 
  Mild symptoms 67 (30.6) 
  Moderate symptoms 61 (27.9) 
  Severe symptoms 39 (17.8) 
Treatment Regimen   
  Always received on prophylaxis therapy 121 (55.3) 
  Received both prophylaxis and on-demand therapy  31 (14.2) 
  Always received on on-demand therapy 45 (20.5) 
Number of bleeding episodes in the past year, mean (sd) 11.69 (±19.1) 
Hemophilia-related surgery    
  Yes 73 (33.3) 
  No 124 (56.6) 
Number of hemophilia-related surgeries in the past year, 
mean (sd) 3.64 (±3.9) 
Comorbidities   
  Hepatitis C 80 (36.5) 
  HIVˠ 26 (11.9) 
  Depression 84 (38.4) 
  Inhibitors to clotting factor 41 (18.7) 
Annual number of hemophilia-related visits, mean (sd)   
  Hemophilia Treatment Center (HTC) 2.23 (±3.1) 
  Hematologist outside a HTC 0.83 (±1.8) 
  Primary Care Practitioner 2.42 (±4.2) 
SD standard deviation 
*Other includes American Indian/Alaskan Native, Asian/Indian Asian, 
Native Hawaiian/Other Pacific Islander, Hispanic, etc. 
†Other includes divorced, separated, widowed, and not married, living with 
partner 
‡Other includes retired, home–maker, student, seeking work, etc. 
ˠHIV - Human Immuno Deficiency Virus. 
 
 
The mean PCS and MCS summary scale scores for the study sample were 43.68 (±10.19) 
and 46.48 (±10.09).  Kurtosis and skewness coefficients were calculated in order to check for 
multivariate normality.  Absolute values of the skew index and kurtosis index for all study 
variables were found to be less than 3.0 and less than 10.0 respectively.  Therefore the data were 
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considered to be normally distributed (Kline, 2005).  Descriptive statistics for all study measures 
have been reported in Table 4.2 below.
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Table 0.2: Descriptive statistics for the variables in the study model 
Measure N Mean (SD) 
Possible 
Range Minimum  Maximum Skewness Kurtosis 
            Statistic 
Std. 
Error Statistic 
Std. 
Error 
HAQ-DI 198 0.563 (0.64) 0 to 3 0.00 3.00 1.306 0.166 1.104 0.330 
Self-Efficacy  198 32.952 (5.80) 10 to 40 11.00 40.00 -1.292 0.167 2.338 0.333 
Social Support 198 5.632 (1.19) 1 to 7 1.50 7.00 -1.062 0.169 0.754 0.336 
Adaptive Coping 198 38.589 (10.04) 16 to 64 16.00 56.00 -0.525 0.173 0.002 0.344 
Maladaptive Coping 198 20.788 (7.84) 10 to 40 10.00 40.00 0.629 0.173 -0.241 0.344 
Physical Component 
Score 219 43.68 (10.19) 0 to 100 16.95 67.63 -0.620 0.164 0.613 0.327 
Mental Component 
Score 219 46.48 (10.09) 0 to 100 15.75 68.91 -0.719 0.164 1.230 0.327 
Note: HAQ-DI, Health Assessment Questionaire Disability Index  
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Bivariate Analysis 
Bivariate correlations between study variables were computed using the Pearson’s 
correlation coefficient.  Statistically significant correlations were seen between all variables in 
the SEM model and PCS and MCS summary score among adults with hemophilia except for the 
correlation between social support and PCS.  All bivariate correlations have been reported in 
Table 4.3 below. 
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Table 0.3: Correlations among study variables 
 HAQDI Social 
Support 
Self-
Efficacy 
Adaptive 
Coping 
Maladaptive 
Coping 
PCS MCS 
HAQDI 1 - - - - - - 
Social 
Support 
-.143* 1 - - - - - 
Self-Efficacy -.320** .335** 1 - - - - 
Adaptive 
Coping 
.194** .207** .032 1 - - - 
Maladaptive 
Coping 
.294** -.092 -.117 .597** 1 - - 
PCS -.542** .130 .217** -.160* -.181* 1 - 
MCS -.287** .310** .327** -.147* -.438** .122 1 
Note: HAQ-DI, Health Assessment Questionaire Disability Index; PCS, Physical 
Component Score; MCS, Mental Component Score 
*. Correlation is significant at the 0.05 level (2-tailed).    
**. Correlation is significant at the 0.01 level (2-tailed).    
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Psychosocial predictors of HRQOL 
Based on the hypothesized relationships, a structural equation model was tested.  This 
model tested the mediating role of social support and coping in the relationship between 
disability and HRQOL.  Additionally, model also tested the moderating effect of self-efficacy on 
the relationship between social support and HRQOL as well as coping and HRQOL (Figure 4.1).  
This model had a poor fit (Chi-square [df] = 459.153 [193]; RMSEA [90% CI] = 0.168 [0.148-
0.188]; CFI = 0.320; TLI = 0.154; WRMR = 1.602).  All the interaction terms testing the 
moderating role of self-efficacy were not statistically not significant at α = 0.05.  Overall we 
were not able to obtain a model with acceptable fit to identify psychosocial predictors of 
HRQOL among adults with hemophilia by employing the hypothesized moderated mediation 
approach.   
In the context of the stress-appraisal-coping framework, previous studies have also examined the 
role of self-efficacy as a mediator of the relationship between social support or coping and the 
adaptational outcome of interest (i.e., physical functioning, medication adherence) among 
patients with HIV and osteoarthritis (DiIorio et al., 2009; EunSeok, Erlen, Judith A, Kim, 
Sereika, & Caruthers, 2008; McKnight et al., 2010).  Therefore, as a post-hoc analysis, the role 
of self-efficacy as mediator of the relationship between social support and HRQOL as well as 
coping and HRQOL instead of its moderating effect was tested.  The serial mediator model 
which was tested has been shown in Figure 4.2.  This model had an acceptable fit as indicated by 
the model fit indices (Chi-square [df] = 321.645 [140]; RMSEA [90% CI] = 0.082 [0.070-0.094]; 
CFI = 0.930; TLI = 0.909; WRMR = 1.084).  The model fit statistics for both study models have 
been presented in table 4.4.  The final model explained 65.3% of the variance in the LPF and 
60.3% of the variance in the LMF. 
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Figure 0.2: Final study model based on structural equation modeling 
Goodness of fit statistics for the following model (Chi-square [df] = 321.645 [140]; RMSEA [90% CI] = 0.082 [0.070-0.094]; CFI = 
0.930; TLI = 0.909; WRMR = 1.084). Only significant standardized relationships have been shown in the figure below. Non-
significant paths and item loadings of the SF-12v2 items on the two latent factors have not been shown. 
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Table 0.4: Summary of fit indices for the models examining psychosocial predictors of health-
related quality of life among adults with hemophilia 
Fit Statistics  Model 1 Model 2 
   
Chi-square (df) 459.153 (193) 321.365 (140) 
CFI 0.320 0.930 
TLI 0.154 0.909 
RMSEA (90% CI) 0.168 (0.148 - 0.188) 0.082 (0.070 - 0.094) 
WRMR 1.602 1.084 
Model 1 - Testing the role of self-efficacy as a moderator in the 
stress-appraisal-coping framework;                                                                                     
Model 2 - Testing the role of self-efficacy as a mediator in the 
stress-appraisal-coping framework.                                                                                                  
Note: df, degrees of freedom; CFI, Comparative Fit Index; TLI, 
Tucker-Lewis Index; RMSEA, Root Mean Square Error of 
Approximation; WRMR, Weighted Root Mean Square Residual; 
CI, Confidence Interval. 
 
The significant direct and indirect effects of the study variables for model 2 have been 
reported in table 4.5 below.  The indirect effects in the model were tested for statistical 
significance using the Sobel test and bias-corrected bootstrap confidence intervals with 500 
draws. As hypothesized all study variables had a direct effect on the LPF and LMF except social 
support and adaptive coping.  Disability as measured on the HAQ-DI had a significant direct 
effect on the LPF (standardized indirect effect = -0.390) as well as on the LMF (standardized 
indirect effect = -0.244).  Maladaptive coping had a significant negative impact on the LPF 
(standardized indirect effect = -0.316) and even worse impact on the LMF (standardized indirect 
effect = -0.536).  Self-efficacy had a significant positive effect on the LPF (standardized indirect 
effect = 0.091) and LMF (standardized indirect effect = 0.221).   
The impact of disability on LPF was mediated by self-efficacy (standardized indirect 
effect = -0.032) and maladaptive coping (standardized indirect effect = -0.109).  Self-efficacy 
(standardized indirect effect = -0.079) and maladaptive coping (standardized indirect effect = -
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0.185) also mediated the impact of disability on LMF.  The effect of social support on LMF was 
also mediated by self-efficacy (standardized indirect effect = 0.063).
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Table 0.5: Unstandardized path coefficients for the study model examining psychosocial predictors of health-related quality of life 
among adults with hemophilia 
Path Estimate (SE)ˠ p-value* 
Direct Paths   
Disability→Social Support -0.089 (0.067) 0.184 
Disability→Adaptive Coping  0.194 (0.060) 0.001 
Disability→Maladaptive Coping  0.345 (0.072) <0.0001 
Disability→Self-Efficacy -0.356 (0.052) <0.0001 
Disability→Latent Physical Factor -0.390 (0.074) <0.0001 
Disability→Latent Mental Factor -0.244 (0.084) 0.001 
Social Support→Self-Efficacy  0.283 (0.065) <0.0001 
Social Support→Latent Physical Factor  0.001 (0.057) 0.988 
Social Support→Latent Mental Factor  0.118 (0.070) 0.128 
Adaptive Coping→Self-Efficacy  0.055 (0.115) 0.636 
Adaptive Coping→Latent Physical Factor  0.030 (0.063) 0.651 
Adaptive Coping→Latent Mental Factor  0.096 (0.091) 0.319 
Maldaptive Coping→Self-Efficacy -0.023 (0.106) 0.832 
Maldaptive Coping→Latent Physical Factor -0.316 (0.079) <0.0001 
Maladaptive Coping→Latent Mental Factor -0.536 (0.089) <0.0001 
Self-Efficacy→Latent Physical Factor  0.091 (0.049) 0.046 
Self-Efficacy→Latent Mental Factor  0.221 (0.060) 0.001 
   
Indirect Paths   
Disability→Self-Efficacy→Latent Physical Factor -0.032 (0.019) 0.039 
Disability→Maladaptive Coping→Latent Physical Factor -0.109 (0.035) 0.002 
Disability→Self-Efficacy→Latent Mental Factor -0.079 (0.024) 0.004 
Disability→Maladaptive Coping→Latent Mental Factor -0.185 (0.053) 0.005 
Social Support→Self-Efficacy→Latent Mental Factor  0.063 (0.022) 0.004 
Note: SE, Standard Error   
ˠParameter estimates are obtained from bias corrected bootstrap estimates  
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*p-values and standard errors are obtained from Sobel 
test 
  
Covariance between residual terms of adaptive coping and maldaptive coping as well as 
adaptive coping and social support have been omitted from the table for simplicity, but 
were estimated in the model. 
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DISCUSSION 
Although several previous studies have examined predictors of HRQOL among patients 
with hemophilia, the majority of these studies have focused on the role of clinical (i.e., disease 
severity, presence of comorbidities such as hepatitis C, HIV, or inhibitors to clotting factor) and 
socio-demographic factors (i.e., age) (Miners et al., 1999; Szucs, Öffner and Schramm, 1996).  
However, these studies have generally overlooked the role of psychosocial variables such as 
social support, coping strategies, and self-efficacy.  These factors have been identified as key 
determinants of HRQOL among patients with other diseases (Luszczynska et al., 2007a; 
McKnight et al., 2010).  The current study sought to identify psychosocial predictors of HRQOL 
by employing Lazarus and Folkman’s cognitive behavioral model of stress, appraisal, and 
coping.  The relationships between constructs such as disability, social support, coping strategies 
adopted, patient self-efficacy, and HRQOL (operationalized as the LPF and the LMF) were 
examined in the current study using a structural equation modeling. 
Results from the SEM analysis suggested a direct as well as an indirect effect of 
disability on HRQOL among adults with hemophilia.  As hypothesized, disability had a 
significant negative direct effect on the LPF and the LMF.  A study by Santavirta and colleagues 
suggested disability had a significant negative impact on the physical activity level and 
psychosocial well-being assessed using the Rand 36-item Health Survey v1.0 among adults with 
hemophilia in Sweden (Santavirta et al., 2010).  The detrimental impact of disability on physical 
and psychosocial functioning has also been reported among adults with hemophilia in the 
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Netherlands (Triemstra et al., 1998).  With respect to the individual domains of HRQOL, the 
current study suggested that the negative impact of disability on physical HRQOL was much 
greater than its impact on mental HRQOL.  Patients with hemophilia suffer from repeated 
bleeding into joints and large muscle groups of the body.  This can lead to long term impairments 
in mobility, reduction in the range of joint motion and eventually impact physical HRQOL 
(Aznar et al., 2009; Mackensen, 2007).  Although hemophilia does impact the mental well-being 
of patients as well, this is to a much lesser extent.  In fact some studies in the literature have 
suggested the mental HRQOL of adults with hemophilia was similar to the general healthy 
population (Aznar et al., 2009; Lindvall et al., 2012; Molho et al., 2000; Poon et al., 2014).  
Considering these limitations placed by hemophilia on the physical, mental, and social aspects of 
the lives of patients, it is reasonable to expect a negative relationship between disability and the 
physical and mental HRQOL of the study population. 
The impact of coping on HRQOL among adults with hemophilia has not been assessed 
extensively in the existing literature.  The findings from the current study suggested that 
maladaptive coping had a significant negative impact on the physical and mental HRQOL of 
adults with hemophilia.  A study by Binnema et al. (2014) among severe hemophilia patients in 
the Netherlands suggested that patients’ use of maladaptive coping was associated with poor 
socio-psychological health, lesser participation in daily activities, and reduced social interaction.  
Santavirta and colleagues found that Swedish patients with bleeding disorders used maladaptive 
coping strategies like distraction and catastrophizing more often than adaptive coping strategies 
such as reinterpreting pain and the use of maladaptive coping strategies was significantly 
associated with poor psychosocial well-being (Santavirta et al., 2010).  A similar finding was 
reported by Klein and colleagues among hemophilia patients with HIV (Klein et al., 1994).  In 
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the current study, maladaptive coping also mediated the relationship between disability and 
physical as well as mental HRQOL.  These results suggest that an increase in hemophilia-related 
disability may lead to a greater adoption of maladaptive coping strategies which in turn would be 
associated with lower physical and mental HRQOL.  Santavirta and colleagues (2010) reported a 
similar finding where coping was found to mediate the relationship between disease severity and 
psychosocial well-being among adults with hemophilia.  Overall, the impact of disability on 
HRQOL may be alleviated with the restricted use of maladaptive coping strategies.  Clinicians as 
well as caregivers of adults with hemophilia must encourage patients to develop better coping 
mechanisms which could help in the long-term management of their symptoms and possibly 
improve their HRQOL. 
A positive direct effect of self-efficacy on physical as well as mental HRQOL was 
observed in this study.  Self-efficacy has been found to predict better functional status among 
patients with arthritis (Maly, Costigan, & Olney, 2006; Marks & Allegrante, 2005) and sickle 
cell disease (Clay & Telfair, 2007).  Similarly, a study among adult hemophilia patients reported 
that higher self-efficacy scores were significantly correlated with higher HRQOL (Lock et al., 
2014).  Additionally as hypothesized, we also found that self-efficacy mediated the effect of 
disability on physical and mental HRQOL.  In the context of the stress, appraisal, coping 
framework employed by the current study, self-efficacy served as an important concept in the 
self-appraisal process which can favorably impact self-reported outcomes of the adaptational 
process (HRQOL in this case) more so than other objectively measured outcomes (McKnight et 
al., 2010).  Family members and clinicians should therefore target improving positive strengths 
such as self-efficacy among adults with hemophilia.  Interventions designed to improve self-
efficacy could result in long-term functional and psychosocial benefits in this patient population 
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and diminish the negative impact of disease severity, pain, and disability on patient HRQOL.  No 
support was found for the moderating role of self-efficacy in the current study. 
Finally, the study results suggested that social support did not have a direct impact on the 
physical or mental HRQOL.  Also, we did not find any support for the hypothesis that social 
support will mediate the relationship between disability and HRQOL.  Triemstra and colleagues 
(1998) reported a similar finding among Dutch hemophilia patients where social support was not 
found to be a mediator of the relationship between disability and well-being.  However, a 
significant indirect effect of social support on mental HRQOL through self-efficacy was 
observed among adults with hemophilia in the current study.  A core tenet of the social cognitive 
theory is social support which is important for the development of self-efficacy beliefs (Bandura, 
1994).  Social support in the form of emotional support (encouragement, affirmation), 
informational support (providing advice and guidance to boost one’s positive mood), and 
instrumental help from people who are close to the patient may positively affect self-efficacy 
beliefs.  According to Bandura’s social cognitive theory, social support can have an enabling 
effect on self-efficacy.  Individuals receiving adequate social support are likely to harbor 
stronger self-efficacy beliefs.  These in turn will positively impact health-related outcomes such 
as HRQOL.  Therefore the benefits of receiving adequate social support on HRQOL may be 
partially mediated by self-efficacy.  Such a relationship has been found to exist among patients 
with HIV, where social support impacted medication adherence to HAART therapy indirectly 
via self-efficacy (Cha, Erlen, Kim, Sereika, & Caruthers, 2008; Luszczynska et al., 2007a; 
Simoni, Frick, & Huang, 2006). 
Overall, the results of this study have both practical and theoretical implications.  From a 
practical perspective, our results can be used to design interventions to improve social support, 
 137 
 
 
increase the use of adaptive and restrict the use of maladaptive coping strategies, and develop 
stronger self-efficacy beliefs among adults with hemophilia.  Such interventions could 
potentially improve functional status, psychosocial well-being and the overall HRQOL in this 
patient population.  From a theoretical perspective we found that the Lazarus and Folkman’s 
cognitive behavioral model of stress, appraisal, and coping worked well in trying to explain the 
nature of the relationship between disability, resulting from hemophilia, and HRQOL.  This was 
the first US based study to use an SEM based approach toward identifying psychosocial 
predictors of HRQOL among adults with hemophilia.  The information from this study can help 
researchers modify their understanding of HRQOL among hemophilia patients.  In the future, it 
would be very important to consider the role of psychosocial variables such as social support, 
coping, and self-efficacy while designing studies in which HRQOL is a key outcome parameter.  
Excluding such important determinants may lead to biased estimates and an incorrect 
understanding of HRQOL among patients with hemophilia and other bleeding disorders. 
A few limitations must be considered while interpreting the results of this study.  First, 
the cross-sectional nature of the study precludes us from drawing any causal inferences despite 
the findings of the study which support the proposed theoretical model.  The proposed causality 
of the model is based on plausible and theoretical arguments which must be tested using 
longitudinal studies in the future.  The study employed a national convenience sample of 
hemophilia patients.  This may limit the generalizability of the study results.  To the best of our 
knowledge, this is the first US based study to employ such a large sample size of hemophilia 
patients.  We recruited patients through multiple sources including online patient panels, private 
patient communities on social media websites as well as at hemophilia treatment centers in order 
to improve study generalizability.  However, future studies should try to employ probability 
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sampling based strategies to recruit rare disease patients.  Future studies must also try to assess 
the role of psychological variables such as depression and anxiety in the relationship between 
disability and HRQOL among hemophilia patients.  These variables have been shown to be key 
predictors of patient well-being in previous studies (Triemstra et al., 1998). 
The current study builds on existing literature among adults with hemophilia.  The current study 
employed the stress, appraisal, and coping framework to identify psychosocial predictors of 
HRQOL among adults with hemophilia.  Study results revealed the key role played by variables 
such as maladaptive coping, self-efficacy, and social support in influencing the HRQOL of 
adults with hemophilia.  It was found that maladaptive coping had a negative influence on both 
physical and mental HRQOL.  Maladaptive coping also mediated the relationship between 
disability and HRQOL.  Stakeholders must encourage the restricted use of maladaptive coping 
strategies in order to minimize its detrimental impact on HRQOL.  Self-efficacy had a significant 
direct positive relationship with HRQOL.  Self-efficacy also mediated the impact of disability on 
HRQOL and intensified the beneficial impact of social support on HRQOL.  Caregivers, policy 
makers, and clinicians must pay heed to these modifiable psychosocial variables in providing 
care to adults with hemophilia in order to maximize the benefit which patients may receive from 
treatment and improve their HRQOL. 
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Dear Sir/Madam, 
We are conducting an online survey to gather information on the experiences of individuals with 
hemophilia.  The survey will assess the disease burden and quality of life among individuals with 
hemophilia. This study is being conducted by researchers at the University of Mississippi - School 
of Pharmacy. This study is part of a Ph.D. student’s research project.  We would appreciate it very 
much if you could take a few minutes to complete the online survey.  Your response is very 
important in helping us achieve accurate estimates of the impact of hemophilia on quality of life 
and assess the burden of this disease. 
Adult (18 years of age and older) patients with hemophilia A or B are eligible to participate 
in this study.  The survey should take no longer than 15-20 minutes to complete.  Upon completion 
of the survey, a $10 Amazon gift card will be emailed to you as a token of our appreciation for 
your participation.  In addition, upon the completion of the study an executive summary of the 
study findings will be made available to you. You will be asked to provide an email ID upon the 
completion of the survey so that the research team can send you the gift card and the summary of 
the study results. Your email ID will not be linked with your response or used for any other 
purpose. 
We THANK YOU in advance for your time and contribution in providing us with this valuable 
information.   If you have any questions or need more information about this project, please contact 
Ruchit Shah in the Department of Pharmacy Administration at the University of Mississippi at 
662-801-1520. 
Click on the following link or Copy and Paste it in your internet browser to complete the 
survey: 
http://uofmississippi.qualtrics.com/SE/?SID=SV_51PhfEFYJwLo9o1 
 
Sincerely, 
 
Ruchit Shah, MS     John P. Bentley, Ph.D. 
Ph.D. Candidate      Professor 
Pharmacy Administration    Pharmacy Administration 
The University of Mississippi    The University of Mississippi 
School of Pharmacy     School of Pharmacy 
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Thank you for your willingness to participate in this survey. 
 
GENERAL INSTRUCTIONS: For each of the following questions please check the most appropriate 
response. Please note that there are no right or wrong answers to any of the following questions.  
 
1. Are you 18 years of age or older? 
 Yes 
 No 
 
2. Which of the following conditions do you suffer from? 
 Hemophilia A 
 Hemophilia B 
 Other (please specify) ____________________ 
 
If you answered ‘NO’ on No. 1 or ‘OTHER (please specify) on No. 2: 
Unfortunately, this study focuses on adult patients with Hemophilia A or B. Please do not proceed with 
this survey. Thank you for your time. 
 
 
 
 
 
 
PLEASE COMPLETE QUESTIONS ON FRONT AND BACK OF THE FOLLOWING 
PAGES 
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Section I Part A - Your Health and Well-Being 
 
INSTRUCTIONS: This survey asks for your views about your health.  This information will help keep 
track of how you feel and how well you are able to do your usual activities. For each of the following 
questions, please select the option that best describes your answer. 
 
1. In general, would you say your health is: 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor 
 
2. The following questions are about activities you might do during a typical day.  Does your health now 
limit you in these activities?  If so, how much? 
 
 
 
3. During the past 4 weeks, how much of the time have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health? 
 
 
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
a. Accomplished 
less than you would 
like 
          
b. Were limited in 
the kind of work or 
other activities 
          
 
 
 Yes, limited a lot Yes, limited a little No, not limited at all 
a. Moderate activities, such 
as moving a table, pushing a 
vacuum cleaner, bowling, or 
playing golf 
      
b. Climbing several flights 
of stairs 
      
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4. During the past 4 weeks, how much of the time have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 
 
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
a. Accomplished 
less than you 
would like 
          
b. Did work or 
other activities less 
carefully than 
usual 
          
 
 
5. During the past 4 weeks, how much did pain interfere with your normal work (including both work 
outside the home and housework)? 
 Not at all 
 A little bit 
 Moderately 
 Quite a bit 
 Extremely 
 
6. These questions are about how you feel and how things have been with you during the past 4 
weeks.  For each question, please give the one answer that comes closest to the way you have been 
feeling.  How much of the time during the past 4 weeks... 
 
 All of the time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
a. Have you felt 
calm and 
peaceful? 
          
b. Did you have 
a lot of energy? 
          
c. Have you felt 
downhearted 
and depressed? 
          
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7. During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
 All of the time 
 Most of the time 
 Some of the time 
 A little of the time 
 None of the time 
 
 
 
SECTION I:  PART B – Your Ability to Function in Daily Life 
 
INSTRUCTIONS: In this section we are interested in learning about your ability to function in daily life.  
Please select the response which best describes your usual abilities OVER THE PAST WEEK: 
 
Dressing and Grooming     
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Dress yourself, 
including shoelaces 
and buttons? 
        
b. Shampoo your 
hair? 
        
 
 
Arising 
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Stand up from a 
straight chair? 
        
b. Get in and out of 
bed? 
        
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Eating 
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Cut your own 
meat? 
        
b. Lift a full cup or 
glass to your 
mouth? 
        
c. Open a new milk 
carton? 
        
 
 
Walking 
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Walk outdoors on 
flat ground? 
        
b. Climb up five 
steps? 
        
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Please check any AIDS OR DEVICES that you usually use for any of the above activities:       
(Please check all that apply) 
 Devices used for dressing (button hook, zipper pull, etc.) 
 Built up or special utensils 
 Crutches 
 Cane 
 Wheelchair 
 Special or built up chair 
 Walker 
 No, I don't use any aids or devices 
 
Please check any categories for which you usually need HELP FROM ANOTHER PERSON: 
(Please check all that apply) 
 Dressing and grooming 
 Arising 
 Eating 
 Walking 
 No, I don't need help from another person 
 
SECTION I:  PART B – Your Ability to Function in Daily Life (continued) 
 
Please select the response which best describes your usual abilities OVER THE PAST WEEK: 
 
Hygiene 
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Wash and dry 
your body? 
        
b. Take a tub bath?         
c. Get on and off 
the toilet? 
        
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Reach 
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Reach and get 
down a 5 pound 
object (such as a 
bag of sugar) from 
above your head? 
        
b. Bend down to 
pick up clothing 
from the floor? 
        
 
 
Grip 
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Open car doors?         
b. Open previously 
opened jars? 
        
c. Turn faucets on 
and off? 
        
 
 
Activities  
Are you able to: 
 
Without ANY 
difficulty 
With SOME 
difficulty 
With MUCH 
difficulty 
UNABLE to do 
a. Run errands and 
shop? 
        
b. Get in and out of 
a car? 
        
c. Do chores such as 
vacuuming or yard 
work? 
        
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Please check any AIDS OR DEVICES that you usually use for any of the above activities:      
(Please check all that apply) 
 Raised toilet seat 
 Bathtub bar 
 Long-handled appliances for reach 
 Bathtub seat 
 Long-handled appliances in the bathroom 
 Jar opener (for jars previously opened) 
 No, I don't use any aids or devices 
 
Please check any categories for which you usually need HELP FROM ANOTHER PERSON: 
(Please check all that apply) 
 Hygiene 
 Reach 
 Gripping and opening things 
 Errands and chores 
 No, I don't need help from another person 
 
Your Activities: To what extent are you able to carry out your everyday physical activities such as 
walking, climbing stairs, carrying groceries, or moving a chair? 
 Completely 
 Mostly 
 Moderately 
 A little 
 Not at all 
 
Your PAIN: How much pain have you had IN THE PAST WEEK?     On a scale of 0 to 100 (where zero 
represents “no pain” and 100 represents “severe pain”), please record the number below. 
____________________     
 
Your HEALTH: Please rate how well you are doing on a scale of 0 to 100 (0 represents “very well” and 
100 represents “very poor health”), please record the number below. 
____________________ 
 
  
 160 
 
 
SECTION I:  PART C – Your Self-Efficacy 
 
INSTRUCTIONS: Below are ten statements about yourself which may or may not be true. Please 
indicate your agreement with each item by selecting the appropriate option.     Please be open and honest 
in your responding. 
 
 Not at all true Hardly true Moderately true Exactly true 
a. I can always 
manage to solve 
difficult problems if 
I try hard enough. 
        
b. If someone 
opposes me, I can 
find the means and 
ways to get what I 
want. 
        
c. It is easy for me 
to stick to my aims 
and accomplish my 
goals. 
        
d. I am confident 
that I could deal 
efficiently with 
unexpected events. 
        
e. Thanks to my 
resourcefulness, I 
know how to handle 
unforeseen 
situations. 
        
f. I can solve most 
problems if I invest 
the necessary effort. 
        
g. I can remain calm 
when facing 
difficulties because I 
can rely on my 
coping abilities. 
        
h. When I am 
confronted with a 
problem, I can 
usually find several 
solutions. 
        
i. If I am in trouble, 
I can usually think 
of a solution. 
        
j. I can usually 
handle whatever 
comes my way. 
        
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SECTION I:  PART D – Your Social Support 
 
INSTRUCTIONS: We are interested in how you feel about the following statements. Read each 
statement carefully. Please indicate your level of agreement with each statement. 
 
 
 
Very 
strongly 
disagree 
Strongly 
disagree 
Mildly 
disagree 
Neutral 
Mildly 
agree 
Strongly 
agree 
Very 
strongly 
agree 
a. There is a 
special person 
who is around 
when I am in 
need. 
              
b. There is a 
special person 
with whom I 
can share my 
joys and 
sorrows. 
              
c. My family 
really tries to 
help me. 
              
d. I get the 
emotional help 
and support I 
need from my 
family. 
              
e. I have a 
special person 
who is real 
source of 
comfort to me. 
              
f. My friends 
really try to 
help me. 
              
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SECTION I:  PART D – Your Social Support (continued) 
 
Please indicate your level of agreement with each statement. 
 
 
Very 
strongly 
disagree 
Strongly 
disagree 
Mildly 
disagree 
Neutral 
Mildly 
agree 
Strongly 
agree 
Very 
strongly 
agree 
g. I can count 
on my friends 
when things 
go wrong. 
              
h. I can talk 
about my 
problems 
with my 
family. 
              
i. I have 
friends with 
whom I can 
share my joys 
and sorrows. 
              
j. There is a 
special 
person in my 
life who 
cares about 
my feelings. 
              
k. My family 
is willing to 
help me 
make 
decisions. 
              
l. I can talk 
about my 
problems 
with my 
friends. 
              
 
SECTION I:  PART E – Your Coping Strategies 
 
INSTRUCTIONS: These items deal with ways you've been coping with the challenges of having 
hemophilia. There are many ways to try to deal with problems. These items ask what you've been doing 
to cope with this one.  Different people deal with things in different ways, but we are interested in how 
you've tried to deal with it. Each item says something about a particular way of coping. We want to know 
to what extent you've been doing what the item says. Don't answer on the basis of whether it seems to be 
 163 
 
 
working or not - just whether or not you're doing it. Use the response choices provided below. Please 
select your response for each question. Try to rate each item separately in your mind from the 
others.  Make your answers as true FOR YOU as you can. 
 
 
 
I haven't been 
doing this at all 
I've been doing 
this a little bit 
I've been doing 
this a medium 
amount 
I've been doing 
this a lot 
a. I've been turning 
to work or other 
activities to take my 
mind off things. 
        
b. I've been 
concentrating my 
efforts on doing 
something about the 
situation I'm in. 
        
c. I've been saying 
to myself "this isn't 
real". 
        
d. I've been getting 
emotional support 
from others. 
        
e. I've been giving 
up trying to deal 
with it. 
        
f. I've been taking 
action to try to 
make the situation 
better. 
        
g. I've been refusing 
to believe that it has 
happened. 
        
h. I've been saying 
things to let my 
unpleasant feelings 
escape. 
        
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SECTION I:  PART E – Your Coping Strategies (continued) 
 
INSTRUCTIONS: Use the response choices provided below. Please select your response for each 
question. Try to rate each item separately in your mind from the others.  Make your answers as true FOR 
YOU as you can. 
 
I haven't been 
doing this at all 
I've been doing 
this a little bit 
I've been doing 
this a medium 
amount 
I've been doing 
this a lot 
i. I’ve been getting 
help and advice 
from other people. 
        
j. I've been trying to 
see it in a different 
light, to make it 
seem more positive. 
        
k. I’ve been 
criticizing myself. 
        
l. I've been trying to 
come up with a 
strategy about what 
to do. 
        
m. I've been getting 
comfort and 
understanding from 
someone. 
        
n. I've been giving 
up the attempt to 
cope. 
        
o. I've been looking 
for something good 
in what is 
happening. 
        
p. I've been making 
jokes about it. 
        
q. I've been doing 
something to think 
about it less, such as 
going to movies, 
watching TV, 
reading, 
daydreaming, 
sleeping, or 
shopping. 
        
r. I've been 
accepting the reality 
of the fact that it has 
happened. 
        
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SECTION I:  PART E – Your Coping Strategies (continued) 
 
INSTRUCTIONS: Use the response choices provided below. Please select your response for each 
question. Try to rate each item separately in your mind from the others.  Make your answers as true FOR 
YOU as you can. 
 
 
I haven't been 
doing this at all 
I've been doing 
this a little bit 
I've been doing 
this a medium 
amount 
I've been doing 
this a lot 
s. I've been 
expressing my 
negative feelings. 
        
t. I've been trying to 
find comfort in my 
religion or spiritual 
beliefs. 
        
u. I’ve been trying 
to get advice or help 
from other people 
about what to do. 
        
v. I've been learning 
to live with it. 
        
w. I've been 
thinking hard about 
what steps to take. 
        
x. I’ve been 
blaming myself for 
things that 
happened. 
        
y. I've been praying 
or meditating. 
        
z. I've been making 
fun of the situation. 
        
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SECTION I:  PART F – Your Symptom Severity 
 
1. When thinking about all of the hemophilia-related symptoms that you may have experienced during the 
past 4 weeks, please indicate the one option that best describes how your symptoms overall have been. 
 No symptoms 
 Mild symptoms 
 Moderate symptoms 
 Severe symptoms 
 
 
 
Section II: Information about you and your clinical condition 
 
INSTRUCTIONS: Please answer the following questions to help us better understand your responses.     
 
1. Are you: 
 Male 
 Female 
 
2. What is your current age? 
 
____________________ years 
 
3. Which of the following best describes your race or ethnicity?  
 African American/Black 
 American Indian/Alaska Native 
 Asian 
 Hispanic 
 Native Hawaiian/Other Pacific Islander 
 White/Caucasian 
 Other (please specify) ____________________ 
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4. Which of the following describes your current marital status? 
 Never Married 
 Married 
 Divorced 
 Separated 
 Widowed 
 Not married, living with partner 
 
5. What is the highest level of education you have completed? 
 Less than high school 
 High school/GED 
 Some college 
 2 year college degree 
 4 year college degree 
 Professional degree 
 Masters' degree 
 Doctoral degree 
 
6. Which of the following describes your main occupation? 
 Employed/Self-employed full time 
 Employed part-time 
 Retired 
 Home-maker 
 Student 
 Seeking work 
 Other (please specify) ____________________ 
 
7. Please indicate the region of the country in which you reside. 
 Northeast 
 Midwest 
 South 
 West 
 
8. Do you currently have health insurance? 
 Yes  
 No [If you selected this, SKIP No. 9, and GO TO No. 10] 
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9. What type of health insurance do you currently have? 
 Public insurance (e.g. Medicare, Medicaid, VA) 
 Private insurance 
 Other (please specify) ____________________ 
 
10. Please indicate your level of disease severity based on your normal blood clotting factor activity 
level.  
 Mild (clotting factor level between 6% - 40%) 
 Moderate (clotting factor level between 1% - 5%) 
 Severe (clotting factor level less than 1%) 
 Not sure 
 
11. Please indicate the number of bleeds you experienced in the last twelve months. 
 
____________________   
 
12. Which of the following best describes the type of treatment you currently receive.  
 Currently on prophylaxis therapy only 
 Received prophylaxis therapy previously but currently on on-demand therapy only 
 Never received prophylaxis therapy and currently on on-demand therapy only 
 Others (please specify) ____________________ 
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13. Have you ever undergone an orthopedic surgery for the treatment of joint damage due to hemophilia? 
 Yes 
 No [If you selected this, SKIP No. 14, and GO TO No. 15] 
 
14. Please indicate the number of orthopedic surgeries you have undergone for the treatment of joint 
damage due to hemophilia. 
 
____________________ 
 
 
 
15. Please indicate whether you currently have or have ever had each of the following conditions.  
 
a. Hepatitis C 
 Never been infected with Hepatitis C 
 Infected with Hepatitis C in the past but not infected currently 
 Currently infected with Hepatitis C 
 Decline to answer 
 
b. HIV 
 Never been infected with HIV 
 Currently infected with HIV 
 Decline to answer 
 
c. Depression 
 Never been diagnosed with depression 
 Previously diagnosed with depression but do not have it currently 
 Currently diagnosed with depression 
 Decline to answer 
 
 170 
 
 
d. Inhibitors to blood clotting factor 
 Never developed inhibitors to blood clotting factor 
 Developed inhibitors to blood clotting factor in the past but not currently 
 Currently have inhibitors to blood clotting factor 
 Decline to answer 
 
16. Please indicate the number of times you have visited each of the following for hemophilia-related 
treatment (e.g. for clotting factor infusions, regular check-ups) in the last twelve months. 
______ Hemophilia Treatment Center (HTC) 
______ Hematologist outside a HTC 
______ Primary Care Practitioner/ General practitioner 
______ Other (please specify) 
 
 
 
Thank you for your participation in this research study! 
 
 
  
 171 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C: IRB Approval Notice 
 
 
 
 
 
 
 
 
 
 
 
 
 172 
 
 
 
 
 173 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V: SUMMARY AND FUTURE RESEARCH 
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STUDY SUMMARY 
Hemophilia is a rare X-linked chronic genetic blood coagulation disorder among males that is 
caused by a deficiency of clotting factors VIII or IX.  It impacts about 400,000 people across the 
world and about 20,000 in the United States (US) (National Hemophilia Foundation, 2014).  
Patients with hemophilia experience bleeding into joints and muscles which in severe cases can 
lead to chronic pain, reduce the range of joint motion and eventually progress to chronic arthritis 
(Dolan et al., 2009).  Also, patients with hemophilia often suffer from comorbidities such as 
infections due to hepatitis C virus (HCV), human immunodeficiency virus (HIV), or tolerance to 
clotting factors in the form of an inhibitor (Franchini & Mannucci, 2009). 
For a patient living with hemophilia, merely treating and preventing bleeding episodes and other 
physical symptoms using clotting factor concentrates is not enough.  Patients with hemophilia 
must be careful about participating in activities such as contact sports because immediate 
bleeding may ensue.  Long-term impairments in mobility and impact on functional status due to 
reduced range of joint motion may also limit the activities in which patients can participate.  This 
can impact social participation and peer integration (Aznar, Magallón, Querol, Gorina, & Tusell, 
2009; Mackensen, 2007).  Patients can be impacted by employment and occupational disabilities 
as well.  Also, the disease can impact the mental well-being of patients within whom signs of 
depression, anxiety and psychological distress are common (Ghanizadeh & Baligh-Jahromi, 
2009).  Thus the physical, mental and social consequences of the disease serve to reduce the 
HRQOL of patients.  Therefore HRQOL assessment is now recognized as an important health 
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outcomes endpoint which can help decide and optimize treatment options among patients with 
hemophilia (Fischer, van der Bom, & van den Berg, 2003).  A key consideration in HRQOL 
assessment is the use of an appropriate instrument.  One of the most commonly used measures of 
HRQOL is the SF-12 Health Survey version 2 (SF-12v2).   
Study 1 
A good HRQOL tool should have the ability to discriminate between individuals based on their 
health status (Guyatt, Feeny, & Patrick, 1993). Therefore it is recommended that the 
psychometric properties of a HRQOL measure must be established in terms of its validity, 
reliability, and responsiveness before its use in a particular population (Patrick & Deyo, 1989).   
Psychometric assessments provide evidence about the appropriateness of use of measures of 
HRQOL in a particular group of patients.  The SF-12 has been previously used to assess HRQOL 
among patients with hemophilia (Duncan, Kronenberger, Roberson, & Shapiro, 2012; Poon, 
Pope, & Tarlov, 2013). However, its psychometric properties in this population had not been 
assessed.  This study provides evidence about the acceptable psychometric properties of the SF-
12v2 among adults with hemophilia in the US.  The SF-12v2 was found to be a valid and reliable 
generic measure of HRQOL among adults with hemophilia.  The scale demonstrated adequate 
factorial, convergent, discriminant, and known-groups validity.  The scale was found to have 
adequate internal consistency reliability and no evidence of the presence of a floor or ceiling 
effect was found.  Overall, the results provide basis for the future use of the SF-12v2 among 
adults with hemophilia and incorporating the HRQOL information obtained from these studies 
into health policy and clinical decision making. 
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Study 2 
When testing HRQOL differences between groups of patients using a well-established measure 
of HRQOL, it is also fundamental that members of different groups assign the same meaning to 
questionnaire items. If it can be shown that patient characteristics (such as age, gender, type of 
disease, disease severity) do not affect the psychometric properties of the observed indicators 
(i.e., questionnaire items), then the assumption of measurement invariance is not violated. If the 
assumption of measurement invariance holds, then the observed differences in HRQOL among 
groups defining the study population are true differences in HRQOL and not measurement 
artifacts.  In the context of the current study, the assumption of measurement invariance was said 
to be met if specific characteristics such as age, disease severity, and treatment regime did not 
influence observed responses to the items on the SF-12v2.  The study results indicated that the 
SF-12v2 was invariant with respect to age of the study participants.  The presence of DIF was 
seen with respect to item 9 while comparing hemophilia patients across different severity levels.  
This item has shown DIF effects among other patient populations as well as in the general US 
population.  Finally, findings for the invariance analysis across hemophilia treatment regimens 
lend support to the interpretation of “approximate invariance”.  Although HRQOL comparisons 
across hemophilia patients on different treatment regimens can be carried out, these results must 
be interpreted with caution.  Overall, the SF-12v2 was largely invariant with respect to age, 
symptom severity, and treatment regimen among a sample of adults with hemophilia. 
Study 3 
While previous studies have emphasized on clinical and socio-demographic determinants, this 
was the first US-based study which critically shifted focus to an assessment of psychosocial 
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predictors of HRQOL among patients with hemophilia. An adapted version of the Lazarus and 
Folkman’s cognitive-behavioral model of stress, appraisal, and coping was employed in order to 
help us examine the interplay between the patient’s use of resources (i.e., social support, coping 
strategies, and self-efficacy) and adaptational health outcomes such as HRQOL.  Study results 
revealed the key role played by variables such as maladaptive coping, self-efficacy, and social 
support in influencing the HRQOL of adults with hemophilia.  Knowledge about these 
psychosocial factors will not only assist healthcare providers and caregivers in improving care 
provided to individuals with hemophilia, but will also enable patients to better understand and 
self-manage their disease condition. Such assessments can assist both clinicians and healthcare 
policymakers in designing programs aimed at increasing the level of social support provided, 
fostering the use of adaptive coping strategies, and overall ensuring better health among these 
patients. 
 This dissertation is a significant addition to the literature concerning HRQOL among 
patients with hemophilia.  The findings of the psychometric evaluation of the SF-12v2 pave the 
way for future use of this instrument in studies concerning HRQOL among adults with 
hemophilia.  The fact that the SF-12v2 was found to be invariant with respect to age, symptom 
severity, and treatment regimen among a sample of adults with hemophilia is a key for future 
studies which may want to carry out HRQOL comparisons across subgroups of hemophilia 
patients.  Researchers would confidently be able to draw conclusions from such studies because 
the observed differences among these patient subgroups would be true differences in HRQOL 
and not measurement artifacts.  Finally, by examining the role of modifiable psychosocial 
variables (social support, coping, and self-efficacy) in predicting the HRQOL of adults with 
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hemophilia, this dissertation highlighted the need for inclusion of these parameters into disease 
management and treatment decisions.  
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DIRECTIONS FOR FUTURE RESEARCH 
The findings from this dissertation project provides different avenues for future research.  
Study 1 
Future studies should adopt a longitudinal design in order to explore the predictive validity and 
test-retest reliability of the SF-12v2 among adults with hemophilia.  A longitudinal design may 
be useful in assessing any response shift in the HRQOL of adults with hemophilia over a period 
of time.  Future studies should also consider using a disease-specific HRQOL measure to 
ascertain the convergent and discriminant validity of the SF-12v2 in this patient population. 
 
Study 2 
Future research should focus on determining whether hemophilia patients interpret items on the 
SF-12v2 equivalently over a longer period of time (i.e., longitudinal measurement invariance).  
Also, considering the DIF effect on item 9 seen in this study and in the existing literature, future 
studies should consider either revising or completely removing this item from the HRQOL 
measure. 
 
Study 3 
Future studies should test the study model using a longitudinal design in order to determine 
whether the direction and causality of the hypothesized relationships in the current study.  Also, 
in order to improve the generalizability of the study results to all US adults with hemophilia, 
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future studies should consider adopting a probability sampling based technique to recruit patients 
into the study.  Future studies must also try to assess the role of psychological variables such as 
depression and anxiety, other appraisal variables (hopelessness, uncertainty, family hardiness) in 
the relationship between disability and HRQOL among hemophilia patients.  Researchers must 
also try to assess the burden of hemophilia on the HRQOL of caregivers of hemophilia patients.  
It may be interesting to examine the relationship between the physical and mental HRQOL of 
patients and caregivers of patients with hemophilia. 
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